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MECHANISMS AND TARGETING OF NEURODEVELOPMENTAL 
REGULATOR REST IN MEDULLOBLASTOMA DISSEMINATION 
 
Keri Callegari, B.S.  
Advisory Professor: Vidya Gopalakrishnan, Ph.D. 
 
 
Molecular subgrouping of medulloblastoma (MB) has produced four subgroups: 
wingless (WNT), sonic hedgehog (SHH), group 3, and group 4. While patients with 
WNT tumors have the best prognosis, patients with SHH tumors have a more variable 
prognosis concurrent with metastatic disease. This subset of SHH patients have 
elevated levels of the neurogenic regulator, RE1 Silencing Transcription factor 
(REST). To understand the role of REST in MB, we utilized a novel transgenic mouse 
model wherein REST expression can be conditionally elevated during postnatal 
development in the cells of origin of SHH MB, cerebellar granule neural progenitors 
(GNPs). While these mice did not form tumors, an abnormal organization of GNPs in 
the cerebella of these mice was observed. Molecular investigation of these REST-
high GNPs revealed heightened expression of the chemokine receptor, C-X-C-motif 
receptor 4 (CXCR4). CXCR4 function has established importance in both cerebellar 
neurodevelopment and MB tumor metastasis. In MB mouse models, increased REST 
expression resulted in increased CXCR4 expression that was related to increased 
tumor dissemination and dramatically reduced survival of mice. Analysis of patient 
samples revealed that REST and CXCR4 levels were concurrently high in patients 
with metastasis in a subset of SHH (SHH-beta) patients. Examination of human MB 
cell lines strengthened the observation that REST elevation increased MB cell 
vii 
 
migration. The final section of my dissertation work has focused on targeting REST 
activity through inhibition of epigenetic cofactor, lysine specific demethylase 1 (LSD1). 
To this end, I examined human MB patient samples for LSD1 expression and 
discovered that while CXCR4 signaling was highly relevant to SHH-beta subgroups, 
LSD1 was increased in the context of REST most strongly in SHH-alpha and SHH-
beta patient groups. In vitro work demonstrated that LSD1 knockdown reduced SHH 
MB cell line viability in the context of normal and high REST. However, irreversible 
inhibition of LSD1 had no effect on cell viability but did exert a REST-dependent 
reduction of migration. Ingenuity pathway analysis of RNA-sequencing data revealed 
that irreversible inhibition of LSD1 reduced cell migration signaling pathways relevant 
to MB. In summary, my work has two major findings. First, in the context of REST 
elevation, CXCR4 expression and signaling increases along with migratory capacity 
of postnatal GNPs that contribute to perturbed development and medulloblastoma 
infiltration. Second, REST activity can be targeted against complex member LSD1 and 
pharmacological targeting of LSD1 with irreversible inhibitors blocks REST-dependent 
MB cell migration. Collectively, my work has demonstrated that elevated REST 
expression in the developing brain can perturb neurodevelopment and influences 
migration signaling pathways to contribute to medulloblastoma dissemination. 
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1.1 Medulloblastoma and pediatric brain cancer 
1.1.1 Epidemiology and clinical features 
Cancer is the second most common cause of death in children under 14 years of 
age. While relatively rare in adults, central nervous system (CNS) tumors account for 1 in 
4 childhood cancers and are second only behind childhood leukemia (Figure 1). While 
childhood leukemia has a higher incidence, the leading cause of cancer death is CNS 
tumors (1). As of 2017, overall ratios comparing sex differences in CNS tumor incidence 
and mortality reveal a slight increase in susceptibility of CNS tumors in male patients, with 
a 1.4 male to female incidence ratio and a 1.5 male to female mortality ratio (1).  
Tumor grade classifications of CNS tumors are based on pathological appearance 
of the tumor tissue. Tumor grades range from I to IV and are established indicators of 
how rapidly a tumor is likely to grow and spread. After development, normal cells of the 
brain differentiate into specialized cells that do not migrate or multiply often.  Low-grade 
tumors contain mostly cells that are differentiated while high-grade tumors consist of 
undifferentiated cells that are rapidly dividing and poorly organized. Across CNS tumors, 
astrocytomas are the most common tumor type. However, a portion of these tumors are 
low grade and not malignant. The most common high-grade, malignant pediatric CNS 
tumor is medulloblastoma (MB), making up 20% of all tumors (2). 70% of MB patients are 
under the age of 20 and MB tumor cells are of embryonic origin.  
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Figure 1. Cancer incidence in patients aged 0-14 years. Together, acute lymphoblastic 
leukemia (26%) and acute myeloid leukemia (5%) make up the most common group of 
childhood cancers. At a 21% incidence, CNS tumors measure up as the second most 
common childhood cancer. Childhood cancer is the second leading cause of death, only 
behind accidents in children from the United States. Data acquired from American Cancer 
Society “Cancer Facts & Figures 2014 (includes the Special Section: Childhood and 
Adolescent Cancer)”. 
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MB is a world health organization (WHO) grade IV, primitive neuroectodermal 
tumor (PNET) that arises subtentorially in the posterior fossa of the brain. The posterior 
fossa includes the hindbrain which contains the cerebellum, medulla, and pons. The 
cerebellum is the most frequent lesion location for MB and is a highly conserved structure 
important for balance and movement. Due to this, tumor growth here often produces 
symptoms like abnormal gait, lack of coordination, and ataxia. Another side effect of 
growing tumors may be increased intracranial pressure due to blockages in the ventricular 
system (Figure 2). Throughout the tissue of the brain, cavities called ventricles are filled 
with cerebral spinal fluid (CSF). CSF is produced by cells within the choroid plexus and 
circulates throughout the CNS within the ventricular space. When tumors grow they may 
occlude the ventricular space. This occlusion can create a build-up of CSF in the brain 
resulting in increased intracranial pressure that contributes to symptoms such as 
headache, nausea, vomiting, and behavioral changes. Pressure on cranial nerves due to 
tumor growth may also cause patients to present with specific ocular and oculomotor 
dysfunctions, such as double vision, dizziness, and/or an inability to focus or follow 
moving visual stimuli.   
Clinical diagnosis of MB is accomplished by performing a magnetic resonance 
imaging (MRI) scan of the patient’s brain with gadolinium contrast-enhancement. These 
MRI agents are able to enter the brains of MB patients due to tumor-associated 
degradation of the blood brain barrier (BBB). Gadolinium-containing agents will permeate 
tumors with increased vascularity and increase contrast in tumors resulting in a defined 
tumor image. If the tumor is a large defined mass in the cerebellum with uniform contrast-
enhancement (although many MB tumors also have necrotic areas that can leave a more 
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variable pattern), the diagnosis will likely be MB.  As 30% of MB tumors spread to other 
CNS locations via CSF, MRI imaging is also performed throughout the spinal cord to 
check for metastasis (3, 4). Another method to check for potential metastasis is to collect 
CSF via lumbar puncture and cytologically analyze the sample to validate whether free-
floating tumor cells are traveling in the CSF. Confirmation of MB diagnosis is achieved by 
histopathology of a biopsy taken at surgical resection. MB has four histological variants: 
Classic, Desmoplastic/Nodular, Desmoplastic/Extensive Nodularity, and Large 
Cell/Anaplastic. Classic MB presents with numerous, densely-packed cells with small 
round nuclei. Desmoplastic MB is also highly cellular but contains “nodes” of densely 
packed cells intermixed with more loosely-packed areas of low cellularity. Large 
cell/anaplastic MB contain large abnormally shaped cells with high proliferative capacity. 
Once MB diagnosis is confirmed, clinical risk can stratify patients into two groups: 
average-risk and high-risk. Patients are considered high-risk if they are less than 3 years 
of age, if there is evidence of disseminated disease, and/or if the tumor resection was 
subtotal ( leaving >1.5 cm2 residual tumor on post-operative MRI) (5, 6). Other high-risk 
factors include large cell/anaplastic tumor histology and molecular expression profiling 
indicative of drug resistance or tumor aggression. Patients that are not high-risk are 
considered average-risk and receive the standard of care which includes local radiation 
therapy and cytotoxic chemotherapeutic drugs. High-risk patients have their spinal cords 
irradiated in addition to focal radiation. Patient prognosis and prediction to standard 
treatment was historically based on clinical risk stratifications and histological analyses. 
However, these clinical means alone were not sufficient to truly predict patient outcomes. 
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Figure 2. Overview of human brain structure and meningeal layering. Sagittal brain 
section showing the cerebral spinal fluid (CSF) filled ventricular system (blue). The 
meninges contain three distinct layers: dura mater, arachnoid mater, and pia mater. CSF 
flows through the subarachnoid space to encapsulate the brain and the ventricles contain 
the choroid plexus which produce CSF. Tumors in the brain stem or cerebellum are 
subtentorial while tumors in the cerebrum are supratentorial. Subtentorial tumors may 
grow large enough to block the fourth ventricle to increase intracranial pressure.  
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1.1.2 Molecular mechanisms and subgrouping 
In attempts to better understand the disease and anticipate patient prognosis, 
various classifications of MB have been established in the past decade. Previous 
classifications of MB were largely determined by clinical manifestations and histology 
which limited predictive value of patient prognosis and treatment aggression. Thanks to 
the medulloblastoma advanced genomic international consortium (MAGIC) and 
sequencing technology advances in the last decade, MB tumors are now further stratified 
based on their molecular make-up. Molecular-based classification of MB has proven to 
predict patient outcomes more accurately than previous methods alone. This movement 
has also paved the way for research into targeted therapies, an area in which pediatric 
brain cancers are severely lacking. In this project, MAGIC analyzed mRNA and miRNA 
expression profiles of 1000 human MB tumor samples.  
Currently, molecular classification of MB contains 4 subgroups: Wingless (WNT), 
Sonic Hedgehog (SHH), Group 3, and Group 4 (7, 8). These subgroups attain their 
namesake through characteristic activation of developmental molecular signaling 
pathways, excluding the less well understood groups 3 and 4. WNT MB tumors are 
characterized by over-activated WNT signaling and have a mostly classic histology. 
Patients with WNT tumors have very good prognosis and can usually be spared from a 
harsh treatment regimen. WNT patients have a long-term survival probability of 90% and 
tumors rarely metastasize or recur after surgery. SHH MB tumors are characterized by 
either perturbed SHH signaling that drives tumor initiation. While most desmoplastic 
tumors are SHH, only 50% of SHH tumors are desmoplastic with the other remaining half 
being either classic or large cell/anaplastic. SHH MB has an interesting temporal 
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incidence as it is frequent in both infants (0-3) and young adults (16+) while relatively rare 
in patients between the ages of 3 and 16. Patient prognosis is mixed with subset of 
patients experiencing very aggressive disease and metastasis.  Group 3 MB tumors are 
considered the most aggressive of the four classifications and frequently metastasize and 
recur. Histology of Group 3 tumors are usually classic or large cell/anaplastic and many 
of these tumors are characterized by MYC oncogene amplification. The MYC gene 
encodes a transcription factor responsible for cell cycle progression, apoptosis, and cell 
transformation. Patient prognosis has been shown to vary with MYC amplification, as 
patients with MYC overexpression have a higher rate of recurrence and death. Group 4 
MB tumors constitute over 30% of MB diagnoses but are the least well understood MB 
subgroup. Patient prognosis is intermediate and interestingly, while males have a higher 
incidence of Group 4 MB (2:1; male:female), 80% of females with Group 4 MB exhibit 
loss of an X chromosome. Gene expression profiling of Group 4 tumors also demonstrate 
an overexpression of neuronal differentiation/development genes. In this past year, 
collaborators of the MAGIC project have further subclassified these four molecular 
subgroups into up to four subtypes (α, β, δ, γ; Figure 3) (7).  
Molecular classification of MB tumors has allowed for much progress in illuminating 
new molecular targets for potential therapeutic use in MB. A major unmet clinical need is 
the identification of targets for treatment of metastatic disease and the drivers of these 
tumor behaviors are largely unknown. My thesis work described here has examined the 
molecular basis of MB dissemination, with a specific focus on SHH MBs, where a subset 
of patients (α and ß) exhibit metastasis. The cells of origin of SHH MB are known and 
mouse models are available making molecular research possible. 
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Figure 3. Graphical summary of 12 medulloblastoma subtypes. WNT, SHH, Group 
3, and Group 4 MB tumors are further subtyped into up to four subtypes (α, β, δ, γ). Age 
groups are defined as infant (0-3), child (3-10), adolescent (10-17), and adult (>17). 
Figure reprinted with permission from Cell Press (Cavalli, et al. 2017. Intertumoral 
Heterogeneity within Medulloblastoma Subgroups. Cancer Cell 31: 737-754 e736.).  
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1.2 At the intersection of normal development and medulloblastoma  
1.2.1 Prenatal development in brief 
The process of mammalian development begins when two gametes (sperm and 
egg) fuse to mark fertilization. Each gamete combines into a single-cell zygote, which 
contains all of the genetic information required generate a fully developed organism. The 
zygote undergoes four initial, symmetrical divisions to initiate the developmental process 
known as cleavage to result in a 16-cell morula. At this point, blastulation begins and the 
cells divide asymmetrically (Figure 4).To give rise to the blastocyst, cells differentiate into 
an outer cell layer (trophoblasts) and an inner cell mass (embryoblasts). As the 
embryoblasts differentiate, they polarize within a ring of the trophoblasts leaving an empty 
cavity termed the blastocoele. The embryoblast will ultimately give rise to the embryo and 
amnion while the trophoblasts become the fetal part of the placenta. The blastocyst 
implants into the uterine wall to receive oxygen and nutrients from the mother and 
complete conception. The next step of embryogenesis is gastrulation, whereby the 
blastula reorganizes into a multilayered structure known as a gastrula. During 
gastrulation, the anterior to posterior (head to tail) orientation, ventral to dorsal (front to 
back) orientation, and the three germinal layers are established. The germinal layers are 
formed as three disks (in order from deepest to most superficial): the endoderm, 
mesoderm, and ectoderm. The endoderm will develop into many interior organs such as 
the intestines, lungs, pancreas, thyroid, and bladder. The mesoderm will spawn the heart, 
bones, muscles, and the beginnings of the circulatory system. And finally, the ectoderm 
layer gives rise to many connective tissues, the eyes, inner ear, outermost layer of skin, 
and central and peripheral nervous systems.  
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Figure 4. Graphical representation of blastulation and neurulation. (top) Fertilization 
results in a zygote that undergoes 4 symmetrical divisions to become a morula. Cells 
within the morula differentiate to allow the formation of a blastocyst. (bottom) Following 
gastrulation and the generation of the three germinal layers (ectoderm, mesoderm, and 
endoderm), the layers organize into the developing embryo. A section of the ectoderm, 
the neural plate, folds inwards on itself to form the neural tube which runs the length of 
the embryo.  
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Focusing on the nervous system from here on, human brain development begins 
as early as the third week of gestation and continues until full brain maturation in 
adulthood (Figure 4). A specialized area of the ectoderm, the neuroectoderm, gives rise 
to the neural plate.  The neural plate is the origin of the entire nervous system and folds 
in on itself to form a tube with open ends. By the fourth week of gastrulation, the open 
ends seal and create a closed neural tube. At this point, the neural tube can be divided 
into 3 major subdivisions that give rise to the different parts of the CNS (Figure 5). These 
divisions begin at the anterior end with the prosencephalon (contains the telencephalon 
(cerebrum) and the diencephalon (the optic vesicles and hypothalamus)). The middle 
region is the mesencephalon (midbrain) and the posterior end is the rhombencephalon 
(contains the metencephalon (the pons and cerebellum) and the myelencephalon (the 
medulla oblongata)). The spinal cord arises from the notochord. Further stratification of 
these areas will give rise to specialized regions in the brain.  
The metencephalon undergoes a few molecular signaling cascades to remain 
separate from the mesencephalon and to begin development of the hindbrain structures 
of the pons and cerebellum. Tight regulation of secreted factor fibroblast growth factor 8 
(FGF8) establishes and maintains this barrier (9). Secreted at the barrier between the two 
vesicles, FGF8 acts as an inhibitor of orthodenticle homeobox 2 (OTX2) expression and 
is coexpressed with gastrulation brain homeobox (GBX2). OTX2 expression helps 
establish the mesencephalic territory while GBX2 expression is responsible for the 
metencephalic region. Temporospatial expression of these players, among others, are 
critical to proper cerebellar patterning and development.  
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Figure 5. Primary and secondary vesicle stages of development. After neural tube 
formation, 3 vesicles are formed with the Prosencephalon being most anterior. Secondary 
vesicle development further divides these regions into 5 developmental regions. 
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The cells that populate the mature cerebellum arise from two germinal zones 
known as the ventricular neuroepithelium (VN) of the fourth ventricle and the rhombic lip 
(RL) (10-12). The VN produces pancreas transcription factor 1 a (Ptf1a+) positive 
GABAergic neurons, including Purkinje cells and postnatal interneurons, and a majority 
of the glia (13). The rhombic lip is the origin of proneural gene atonal homolog 1 positive 
(Math1+) glutamatergic cells and has two distinct upper and lower areas. The upper 
rhombic lip mainly exists as a source of granule neural progenitors (GNPs) while the lower 
rhombic lip largely gives rise to several precerebellar nuclei (14-16). GNPs produced by 
the upper rhombic lip make up the majority of the neuronal cell population in the 
cerebellum and are the most abundant neuron in the brain (17).  
To populate the prenatal cerebellum, Math1+ GNPs migrate rostrally from the RL 
and disperse across the dorsal side of the cerebellar anlage. As these progenitors fill out 
the outermost area of the cerebellar structure, they begin to define what is known as the 
external granule cell layer (EGL). Purkinje cells from the VN migrate micrometers below 
the EGL in the Purkinje cell layer (PL). The space in between these two layers is the 
molecular layer (ML). Further inwards from the PL, is the internal granule cell layer (IGL). 
At this point in development, before birth, the IGL is populated by interneurons and glia 
(the projections of which extend into the EGL). However, in the fully developed 
cerebellum, the IGL mostly contains mature granule neurons.  
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1.2.2 Postnatal development in brief 
Cerebellar development continues to occur postnatally (Figure 6). Predominantly 
residing in the EGL, GNPs proliferate in response to a number of stimuli including SHH 
secreted from the Purkinje cells. At approximately postnatal day 5-8 in mice, the GNPs 
are at the peak of their proliferation. GNPs in the outer EGL proliferate every 18-20 hours 
and this proliferative phase lasts up to 3 weeks in mice and 2 years in humans (18, 19). 
As cells begin the differentiation process, they become post-mitotic and enter the inner 
EGL. Within the inner EGL, GNPs extend small horizontal processes and initiate 
migration tangentially across the EGL over the span of 24-48 hours. Upon contact of the 
GNP with a projection from a highly-specialized radial glia, Bergmann glia, radial 
migration is initiated. GNPs take about 10-11 hours to traverse the molecular layer and 
reach the Purkinje cell layer in this glia-associated migration. At this point, the cells detach 
from the glial process and begin glia-independent migration through the IGL until a 
leading process reaches white matter (18, 20, 101).  
The molecular mechanisms of postnatal GNP migration in the cerebellum are 
complex and continue to be investigated. Molecules involved in tangential migration 
include neurotrophin-3, stromal-derived factor 1 (SDF1), ephrin-B2, and others (21-23). 
Downstream signaling pathways activated by these molecules include calcium signaling, 
cyclic nucleotide signaling, JAK/STAT signaling, and mitogen-activated protein kinase 
(MAPK) signaling. Mechanistically, tangential migration is spurred by secretion of a potent 
chemoattractant, SDF1, by meningeal cells encapsulating the EGL. SDF1 binds to the 
chemokine C-X-C motif receptor 4 (CXCR4) available on the cell surface of GNPs. 
Tangential migration is postulated to help retain cells in the EGL and prevent its premature 
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depletion. Tangential migration ceases when the GNP is in proximity of a projection from. 
Due to still disputed mechanisms, the GNP switches off its tangential migration machinery 
and begins glial-associated radial migration into the IGL. This radial migration is 
established to be dependent on a multitude of signaling stimuli including ephrin-B2 
signaling, brain derived neurotrophic factor (BDNF) secretion, secreted glial factors 
(astrotactin, tenascin, neuregulin, and fibronectin) (101). Done successfully, postnatal 
GNP proliferation and migration results in a complex laminated cerebellar structure 
capable of encoding and transmitting complex neural data.  
  
17 
 
 
Figure 6. Postnatal cerebellar lamination. Proliferating GNPs respond to SHH secreted 
by the Purkinje cells. As they begin the differentiation process, they migrate tangentially 
across the EGL before finding a Bergmann glia projection and migrating radially inwards. 
The mature granule neuron will reside in the IGL for the remainder of its lifespan. 
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1.2.3 Developmental signaling in cancer 
The quest to elucidate mechanisms of MB etiology has discovered various familial 
developmental disorders related to tumorigenesis. Heriditary syndromes that alter 
developmental signaling and predispose children to MB development include Li-Fraumeni 
syndrome, Turcot syndrome, Gorlin’s syndrome, and rhabdoid tumor predisposition 
syndrome (RTPS). Patients with these autosomal dominant disorders have a higher 
incidence of CNS tumor development, including MB (24, 25).  
Li-Fraumeni syndrome patients are plagued by a wide-range of cancers arising 
from germline mutations of the apoptotic and cell cycle regulator, P53 (26, 27). These 
loss of function mutations cause reduced checkpoint control, resulting in unfettered 
proliferation and hindered apoptosis contributing to tumorigenesis in various cell types 
throughout the patient’s body. Turcot syndrome type 2 patients carry a germline mutation 
of the adenomatous polyposis coli (APC) gene which regulates the degradation of beta-
catenin, a WNT pathway player. Loss of function of APC and subsequent accumulation 
of beta-catenin permits overactive WNT signaling and promotes polyposis and lipoma, 
skin cell carninoma, and brain tumor formation (Figure 7) (28-30). In mouse models, loss 
of function mutations in APC or gain of function mutations in beta-catenin in combination 
with P53 mutations in brain lipid binding protein (BLBP) positive cells of the lower RL give 
rise to WNT subgroup MB. Examination of Turcot/Li Fraumeni patients and lineage 
tracing experiments identified BLBP+ progenitors of the lower RL as cells of origin of WNT 
MB (31, 32).  
Gorlin’s syndrome patients are hallmarked by tumor formation, macrocephaly, and 
skeletal and facial abnormalities (33). Tumorigenesis in these patients is caused by a loss 
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of function mutation in the SHH pathway regulator, patched homologue 1 (PTCH1) (34). 
PTCH1 is a twelve transmembrane domain containing receptor that negatively regulates 
smoothened (SMO) localization and signaling when not bound by the SHH ligand (Figure 
8). SMO is a seven-transmembrane domain containing receptor that initiates a signaling 
cascade to activate glioma-associated (Gli) transcription factors 1 and 2. Normally, in the 
absence of SMO activation, Gli is tightly regulated by several proteins. Gli can be 
sequestered by suppressor of fused homolog (Sufu) and/or phosphorylated by glycogen 
synthase kinase-3 beta (GSK3ß), (CK1a), or site-specific phosphorylation of Gli by these 
proteins will either allow for ubiquination and subsequent degradation of Gli or proteolytic 
processing of Gli 1/2 into a Gli 3 isoform. While Gli 1 and 2 are transcriptional activators, 
Gli 3 exists in a NH2-terminal truncated form and is thought to act as a transcriptional 
repressor (35). SHH binding to PTCH1 alleviates suppression of SMO and allows Gli 1/2 
mediated transcription of SHH target genes. The amount of SHH available to bind to 
PTCH1 is tightly regulated by hedgehog-binding proteins (HBPs) which sequester SHH 
away from the PTCH receptor (36). Loss of function mutations of PTCH allow SHH 
signaling to go unchecked and contributes to MB development in GNPs of the cerebellum. 
The results of these discoveries permitted the generation of SHH MB mouse models with 
gain of function SMO mutations and loss of function PTCH1 mutations in GNPs (32, 37).  
It is clear from a majority of the mechanistic studies that MB is a disease of 
hindbrain development gone awry (7, 8, 25, 28, 31, 32, 37). As MB is an embryonal tumor, 
there are many pathways that can be affected as described in this section and in the 
sections above. Postnatally, it is easy to postulate that spontaneous mutations or 
unregulated signaling in the cerebellum could be responsible for MB development. Due 
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to the spatiotemporal requirement of coordinated molecular signaling and cellular 
dynamics, the developing postnatal cerebellum lends itself vulnerable to insult and 
malformation. As previously mentioned, GNPs are established as the cells of origin of 
SHH MB. Developmental signaling pathways involved in GNP renewal and maturation 
have already been implicated in MB pathogenesis. Further, “traffic jams” due to improper 
migration of GNPs of these cells can also contribute to MB initiation and progression (38-
41). For example, overexpression of CXCR4 and SDF1 is observed in MB patient tumor 
samples and the levels of these proteins is negatively correlated with predicted patient 
prognosis (8, 42, 43). Some subsets of MB, like SHH MB, have been extensively studied 
for mechanisms of their CXCR4 overexpression and expression of CXCR4 in these 
tumors has been shown to be largely dependent on SHH activity. The dysregulation of 
CXCR4 has also been demonstrated to occur both within and outside of the context of 
P53 (39, 44, 45).  
As described in the next section, another molecule of increasing interest is the 
canonical neurogenic regulator, restricted element 1 (RE-1) silencing transcription factor 
(REST). Expression of REST has been linked to worsened patient prognosis and 
leptomeningeal dissemination of MB (46, 47). Unpublished work from our lab shows that 
the mechanisms of REST as driver of MB progression is partially due to REST repression 
of PTCH1 and activation of AKT signaling (Dobson 2018 – under review). However, the 
mechanisms by which REST promotes MB tumor dissemination are not clear and is the 
major question of my thesis project.  
 
 
21 
 
 
Figure 7. Graphical summary of canonical WNT signaling pathway. When the 
transmembrane receptor Frizzled is unbound by WNT ligand, it binds and inactivates 
Dishevelled (Dvl). In the cytoplasm, beta-catenin (ß-cat) is bound by a complex comprised 
of axin, adenomatous polyposis coli (APC), and glycogen synthase kinase 3 beta 
(GSK3ß). This complex site-specifically phosphorylates ß-cat and directs it to be 
ubiquinated by beta-transducin repeat containing E3 ubiquitin protein ligase (ß-trcp). In 
its activation state, when WNT is bound to Frizzled, low density lipoprotein receptor 
related protein 5/6 interacts with Frizzled and axin while Dvl is released. Dvl is free to 
disrupt the axin/APC/GSK3ß complex and permits the accumulation of ß-cat in the 
cytoplasm. In this state, ß-cat can translocate to the nucleus and switch on gene 
expression alongside T-cell factor/lymphoid enhancing factor (TCF/LEF).   
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Figure 8. Graphical summary of SHH signaling. In the inactive state, the patched 
receptor (PTCH1) indirectly inhibits membrane localization of the smoothened receptor 
(SMO). Gli transcription factors 1 and 2 are site-specifically phosphorylated by protein 
kinase a (PKa), GSK3ß, and casein kinase 1 alpha (CK1α). This phosphorylation either 
leads to truncation of the NH2-terminus to produce the repressive Gli 3 isoform or 
ubiquitination by ß-trcp. Suppressor of fused homolog (Sufu) also binds Gli 1/2 and 
sequesters it away from functional interactions in the cytoplasm and nucleus. As a ligand, 
SHH can be sequestered away from PTCH1 by hedgehog binding proteins (HBPs) in the 
extracellular space. In the cases above, SHH target gene transcription is repressed. 
When SHH binds to PTCH1, its repression on SMO is ameliorated. Through mechanisms 
not yet fully understood, phosphorylation of Gli by PKa, GSK3ß, and CK1α do not occur 
and Gli 1/2 is able to translocate to the nucleus and turn on SHH target gene expression.  
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1.3 RE-1 silencing transcription factor (REST) in tumor progression 
1.3.1 The field of epigenetics 
The field of epigenetics (and the term itself) was born from experiments by Conrad 
Hal Waddington in 1956. He demonstrated that the thorax and wings of embryo fruit flies 
(Drosophila) could be influenced to develop in different ways based on the exposure of 
the Drosophila embryo to a wide range of temperatures or chemical stimuli (48). While 
the underlying genetic code was the same in each embryo, environmental stimuli could 
alter the fate of developmental process. To further strengthen these experiments, 
Waddington continued to breed these flies and found that even without continued 
exposure to the stimuli and within a few generations, these phenotypes persisted in the 
resulting offspring. This process was termed genetic assimilation, whereby these genetic 
decisions became locked in and a permanently heritable trait.  
The results from his experiments led him to illustrate a model that could postulate 
how the same pluripotent, embryonic cells could differentiate into distinctly different cell 
types. He would represent this developmental landscape as a marble on top of a grooved 
hill where a series of decisions would favor one route over another and ultimately lead to 
one fate versus another (Figure 9). However, the question still left open by these studies 
was whether or not the genetic information was lost with these decisions. Within the 
decade, another set of experiments found that the nucleus of an adult differentiated cell 
still contained all of the genetic information as that from an embryonic one (49). This was 
accomplished by transferring the nucleus from a somatic cell in an adult frog to an 
unfertilized egg. The results demonstrated that the synthetically fertilized egg could fully 
develop without complication. 
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Figure 9. The developmental landscape. The marble represents a pluripotent cell with 
each decision being a molecular event that restricts the potential of cell to become 
anything else until, finally, the cell reaches its ultimate and specialized cell fate. It is 
speculated on whether this model is relevant in stem cell reprogramming. If cells are 
pushed earlier into the undifferentiated form, can the marble truly move back up from their 
specialized groove to become multipotent at one of the transitional grooves? Or are there 
mechanisms that do not allow for full reprogramming? 
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The results of these two monumental experiments primed the postulation that there 
must be a mechanism to modify and regulate the expression of genes without removing 
or losing genetic material. However the discovery that all of the genetic material remains 
intact in every cell, gave rise to two new questions. How does all of the genetic material 
fit into one cell and how is expression of the exact same genetic material regulated to 
give rise to different cell types?  
Our genetic code is made up of double-stranded deoxyribonucleic acid (DNA). 
DNA is built with a series of nucleotides that code for instructions to transcribe ribonucleic 
acid (RNA) that is translated into functional protein units. One human cell contains 
approximately 2 meters DNA in a nucleus with only a 6 micrometer (µm) diameter. 
Further, thanks to its negatively charged phosphate groups, DNA is a highly negative 
polymer that needs to be packaged in a way that is accessible to transcriptional machinery 
and will also not break or tangle. The solution to this packaging conundrum is a series of 
folding and condensation steps into what we know as chromosomes.  
The normal human cell contains 24 chromosomes. Each chromosomes contains 
one very long DNA molecule that is folded with proteins to form a compact structure called 
chromatin. Chromatin is made up of DNA that is folded around positively-charged proteins 
known as histones. Histone proteins exists as octamers that act as spools which DNA 
wraps around 2.5 times before extending “linker DNA” to the next histone. The chromatin 
structure containing these histone spools, and ~146 base pairs of wrapped DNA, occurs 
as a “beads on a string” and the units of these beads are termed nucleosomes.  
Nucleosomes are the basic unit of the chromosome structure. The octamer of 
histones making up the “bead” of the chromosome contain two copies of histone H2A, 
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H2B, H3, and H4 proteins. These histones have “tails” of modifiable amino acids. Arginine 
(R) and lysine (K) residues are popularly modified to influence both chromatin structure 
and recruitment of transcription factors (50-52). These histone tail residues are available 
in the nuclear space to be read and modified by epigenetic enzymes known as readers 
and writers, respectively.  
Some histone tail modifications modify the charge of the protein, either compacting 
the chromatin further (which impedes transcription) or loosening the chromatin to allow 
improved access of genes to transcriptional machinery. For example, histone acetylation 
(the addition of an acetyl group to a histone tail residue) classically neutralizes the 
histones positive charge to contribute to a more open chromatin structure and render the 
DNA more accessible (53). On the other hand, the addition of a methyl group to residues 
(methylation) will hinder the acetylation of the residue and can alter the association of 
other transcription factors. While methylation of H3K9 and H3K27 residues lead to 
repressive states gene expression. Methylation of H3K4 can actually promote 
transcription factor association with the region. Other modifications will promote or deter 
the association of other enzymes including nucleosome remodelers and transcriptional 
machinery. It is also important to note that DNA itself can be methylated and methylation 
occurring on cytosine-phosphate-guanine (CpG) islands found near the transcription start 
site (TSS) of genes silences expression. 
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Figure 10. Chromosomal structure. DNA is wrapped around histone protein octamers 
that comprise nucleosomes. Nucleosomes are arranged in a “bead on the string” fashion 
that is dynamic and can be found in an open or closed conformation that directly affects 
gene expression. Chromatin fibers are made of 30 nanometers of packed chromatin that 
can be further condensed into coils. These coils condense into supercoils that make up 
the hallmark chromosomal shape. Image adapted and reprinted with permission from 
Molecular Cell Biology, 2007 textbook section C “Cell Division, Genetics, and Molecular 
Biology” (Lodish H, Berk A, Zipursky SL, et al. Molecular Cell Biology. 6th edition. New 
York: W. H. Freeman; 2000).   
28 
 
1.3.2 Canonical REST activity as a chromatin remodeler 
REST is a 121 kilodalton (kDa) kruppel-type zinc finger transcription factor. The 
canonical function of REST is to repress neuronal genes in non-neuronal cells and stem 
cells. REST is expressed ubiquitously throughout the body except within the CNS, where 
it is downregulated in differentiated neurons (54). As a master regulator of neurogenesis, 
REST represses neuronal gene expression by binding to 21-23 base pair sequence in 
the regulatory regions (known as RE-1 binding sites) of neuron-specific genes (54-56); 
Chong 1995). First discovered in 1995, REST has been implicated in several important 
diseases and functions including neurogenesis, neurodegenerative disease, cancer, 
ischemia, and aging (57-62).  
While REST binds directly to DNA, REST itself is not responsible for changes in 
gene expression. Instead, REST associates with corepressor and chromatin remodeling 
enzymes through domains located at the amino (N)- and carboxy (C)- termini. Through 
its N-terminus, REST associates with the paired amphipathic helix protein Sin3a 
(mSin3A) corepressor complex. mSin3a further associates with histone deacetylases 1 
and 2 which deacetylate amino acid residues on histone tails to curb transcriptional 
machinery interactions (63). Through its C-terminus, REST associates with the REST 
corepressor (CoREST) complex which is comprised of histone deacetylase 1/2 
(HDAC1/2), lysine specific demethylase 1 (LSD1), euchromatic histone-lysine N-
methyltransferase 2 (G9a), and others (64-66). These epigenetic players act on histone 
tail modifications that exist to alter the promotion of transcriptional machinery interaction 
with specific genes in a spatiotemporal manner. 
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1.3.3 REST in pediatric brain cancer 
A potential role for REST as an oncogene was first described in a study of MB (67). 
REST expression was maintained across three MB cell lines and adenoviral recombinant 
activation of REST target gene expression decreased cell line viability partially though 
triggered apoptosis (67). In another study, REST expression was detectable in 17 out of 
21 MB tumors (6 strong; 11 weak) (68). Further, adenoviral recombinant activation of 
REST target gene expression blocked tumor establishment in vivo. Interestingly, REST 
expression alone is not enough to induce tumorigenesis (69, 70). As for many oncogenes, 
including MYC, a second hit is required for tumorigenesis to occur. Mouse models 
expressing REST with MYC and REST with a lost allele of the PTCH1 receptor develop 
tumors over time (32, 37).  
Experiments performed by previous members of the lab with mice expressing a 
human REST transgene in the context of cells with a lost PTCH1 allele (RESTTG/Ptch+/-), 
demonstrated a dramatic increase in tumor burden coincident with a reduction in tumor 
latency and overall survival. Further examination of tumor samples from these mice 
revealed very aggressive tumor course and leptomeningeal dissemination. 
Mechanistically, these effects were attributed in part to functional loss of heterozygosity 
of the PTCH1 allele, leading to a homozygous null-like phenotype of SHH hyperactivity. 
Further, deregulation of downstream Gli proteins were also observed along with protein 
kinase b (AKT) signaling pathway hyperactivity. These results suggested a deregulation 
of proliferation, differentiation, and survival pathways converging to promote 
tumorigenesis. However, the mechanisms of how REST promotes dissemination 
remained to be understood. 
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 In human samples, elevated REST levels are negatively correlated with patient 
prognosis (47, 67, 71). Increased gene expression and protein levels of REST are 
correlated with poor overall and event-free survival. Further, inhibition or loss-of-function 
mutations in the ubiquitin ligase complex responsible for degrading REST protein have 
been described and implicated in MB. The SCF (SKP1-CUL1-F-box protein) ubiquitin 
ligase complex is comprised of several factors that are responsible for the post-
transcriptional regulation of REST expression. Two main players include beta-transducin 
repeat containing E3 ubiquitin protein ligase (B-TRCP) and S-phase kinase-associated 
protein 1 (SKP1). Previous work has demonstrated that reduction of B-TRCP increases 
REST stability that can contribute to oncogenic transformation of epithelial cells and tumor 
growth of MBs (47, 71, 72). 
From these and other studies highlighting the oncogenic role of REST, therapeutic 
strategies against REST and its cofactors have been developed. Experiments evaluating 
the efficacy of pharmacological inhibitors of HDAC1/2, G9a, LSD1, and the REST 
complex itself have been reported in the literature (47, 73, 74). Inhibitors targeting 
epigenetic modifiers such as histone deacetylases (HDAC), histone methyltransferases 
(HMT), and histone demethylases (HDM) have proven interesting potential targets in the 
hunt for targeted treatments. Mutations in chromatin remodeling enzymes occur across 
all MB subgroups and are promising druggable targets (43, 75). Several studies have 
found some anti-tumorigenic activity with HDAC inhibitors in MB cells and increased 
HDAC activity is established to dysregulate cell cycle (76, 77). Further work in our lab has 
demonstrated a critical role for G9a in repressing the expression of tumor suppressor 
USP37 (46, 73). The activity of the coREST complex as a component of the REST 
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complex has been associated with poor patient prognosis and MB progression (75). 
Additionally, the activity of several individual coREST complex members have been 
implicated in MB tumorigenesis as well, including HDACs and lysine specific demethylase 
1 (LSD1). While HDAC enzymes have been extensively researched and clinical trials are 
ongoing with HDAC inhibitors for several pediatric brain cancers, less is understood about 
the role of LSD1 in MB progression. LSD1 demethylates lysine residues at position 4 and 
9 on histone 3 tails (H3K4/H3K9) to canonically repress transcription. Methylation at these 
residues has been previously reported to be altered in MB and LSD1 itself is upregulated 
in both neuroblastoma and MB (78, 79).  
Since the discovery of LSD1 as a potential target in MB in 2013, little follow-up has 
been completed clarifying its role in MB development. Previous experiments 
demonstrated that LSD1 expression is increased in MB tumors over normal cerebellum 
(78). The authors found no difference in expression between subgroups. This was 
surprising as it is suggested by examination of patient data that LSD1 could be most 
relevant as a target for patients with group 3 and SHH MB. In this study, tumors from 
group 3 and SHH MB patients have dramatic perturbations in H3K4 methylation 
consistent with overactive LSD1 activity (79). Although the above study found no 
difference in expression levels of LSD1 between the various subgroups, enzyme activity 
is harder to quantify. Further, previous studies failed to examine patient outcomes 
including overall survival and metastasis related to LSD1 expression.  
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1.4 Hypothesis and specific aims 
Tumor dissemination is directly related to cell migration. A major goal of my thesis is 
to understand how REST contributes to MB metastasis with a special focus on how REST 
elevation regulates normal migration of GNPs and perturbs this developmentally-
regulated process. To examine these mechanisms, I utilized a transgenic mouse model 
expressing REST in cerebellar GNPs (the cells of origin of SHH MB) to ask how REST is 
affecting normal postnatal processes. In my thesis, I also sought to understand the role 
of REST in MB dissemination in the context of constitutive SHH signaling.  
A second goal is to assess if pharmacological targeting of the REST complex will 
counter these migration advantages in high-REST MB cells. Strategic targeting of REST 
activity is enlivened by REST’s role as a chromatin remodeler and its interactions with the 
coREST complex. The coREST complex contains LSD1, which has been implicated in 
metastasis and viability of various cancer cells.  
The hypotheses of this dissertation are that (a) REST elevation increases GNP 
and SHH MB cell migration to contribute to MB dissemination and (b) that targeting REST-
associated LSD1 will counter the infiltrative behavior of REST-high MB cells. 
Specific Aim 1: To determine the consequence of REST elevation on postnatal cerebellar 
development and GNP migration.  
Specific Aim 2: To evaluate if and how REST-dependent changes in developmental 
signaling pathways influence MB progression. 
Specific Aim 3: To assess if LSD1 can be developed as a therapeutic target for MB. 
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Chapter 2: Materials and Methods 
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Animals  
Briefly, RESTTG mice were generated by using mice expressing a human REST 
transgene under the NeuroD2 promoter that were crossed with Math1-CreER mice 
purchased from Jackson labs. To induce CRE-expression tamoxifen (Sigma‐Aldrich) was 
dissolved in a foil-wrapped falcon tube with corn oil at a concentration of 20 mg/ml 
overnight at 37°C and then stored at 4°C for the duration of injections. Mice were injected 
intraperitoneally with 75 mg tamoxifen/kg body weight from postnatal day 3 to 5. The 
injection site was cleaned before and after injection with 70% ethanol wipes and mice 
were observed following days for tolerance to treatment. 
Xenograft Experiments 
All procedures were done under the guidelines of approved protocols through the 
The University of Texas M.D. Anderson Cancer Center’s (MDACC) institutional animal 
care and usage committee (IACUC). Mice were dually-housed, when possible, and 
maintained at the animal housing facility on south campus of MDACC. Immuno-
compromised non-obese diabetic (NOD) severe combined immunodeficiency (scid) with 
a null mutation in the interleukin2 receptor gamma chain (NOD scid gamma - NSG) mice 
were purchased from Jackson Laboratories (Bar Harbor, ME). Due to these three genetic 
features, NSG mice have reduced innate and adaptive immunity and blocked NK cell 
differentiation. This absence of immunity allows for the efficient grafting of foreign human 
cancer cells. Daoy MB tumor cells tagged with firefly-luciferase were injected 
intracranially following previously established protocol. Briefly, 50,000 cells were injected 
into groups of mice by stereotactic injection using a Harvard Apparatus infusion pump. 
Cells were injected through a 31-gauge burrhole (2mm caudal and 2mm lateral of the 
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lambdoid suture) at a rate of 0.5 ul/minute in a total volume of 3 ul. Mice were subjected 
to bioluminescence imaging weekly and were sacrificed at 3 months post-injection. 
Sacrificed animals were harvested for brain tissue.  
Bioluminescence Imaging 
In vivo imaging system (IVIS) analysis of tumor cell growth was monitored in vivo 
by IVIS Spectrum imaging systems. Imaging was performed in the Small Animal Imaging 
Facility of UTMDACC south campus. 10 minutes previous to imaging, mice were injected 
intraperitoneally with 150 µL of D-luciferin potassium salt diluted at 15 mg/mL in 
phosphate-buffered saline (PBS). Mice were anesthetized with isoflurane 5 minutes after 
D-luciferin injection and placed within IVIS Spectrum. Luminescent images of tumor cells 
were captured and analyzed using the Living Image 3.2 software 
Patient Sample Analysis 
MB patient samples were analyzed from a publicly available NIH database 
(accession number: GSE85217), which is previously published. Expression values were 
available as Log-2 Robust Multi-array Average (RMA) from Affymetrix. These values were 
either normalized using z-score conversion or glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) expression values across each patient sample. Expression 
values were subjected to correlation analyses and patient outcomes (where available) 
were matched to expression values. Heatmaps, correlation coefficients, and volcano plots 
were generated using GraphPad Prism.  
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Cell Culture 
Human MB cell lines Daoy, UW426, D283, D341, and UW288 were obtained from 
the American Type Culture Collection (Manassas, VA, USA). Cells were cultured and 
maintained in either Modified Eagle Medium (MEM) or Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum and 5% non-essential 
amino acids. Primary progenitor cells were harvested from wild-type and RESTTG mice. 
Progenitor cells were maintained and cultured in neurobasal media and expanded using 
SHH activation.  
Viral Transduction 
Short-term transductions with shLSD1 and LSD1 K661A plasmids were completed 
according to standard protocol. For virus generation, 293T cells were cultured in DMEM 
media and transfected with lipofectamine/opti-MEM and virus plasmids containing shRNA 
for LSD1 or LSD1 with K661A mutation. Media was changed after 4 hours and media was 
harvested at 24 and 48 hours and then combined. Collected media was filtered with a 70 
um syringe filter and centrifuged at 1500 rpm for 5 minutes. Supernatant containing virus 
was stored at -80 degrees Celsius. Stable isogenic cell pairs were generated using 
lentiviral vectors containing human REST transgene tagged with green fluorescent 
protein (GFP). Cells were then sorted by fluorescence-associated cell sorting (FACS) 
and/or treated with puromycin (when plasmids contained puromycin N-acetyl-transferase 
(PAC) to confer puromycin toxicity resistance to cells). FACS sorting was completed in 
the Flow Cytometry and Cellular Imaging Core (MDACC) on a Becton Dickinson FACS-
Aria II at an emission wavelength of 488nm in the FITC channel for GFP-positive cells. 
37 
 
Sorted cells were cultured and then separated and frozen into stock cultures at low 
passage. 
RNA-sequencing analyses 
Progenitor samples from WT and RESTTG mice were sent to Active Motif for RNA-
sequencing. Functional analysis was completed using Ingenuity Pathway Analysis. 
Sequence alignments of RNA-sequencing data was completed using Integrative 
Genomic Viewer from Broadstone institute. 
Immunohistochemistry (IHC) 
Paraffin-embedded patient-derived orthrotopic xenograft (PDOX) samples were 
provided by the lab of Xianon-Li at Texas Children’s Hospital and experiments were 
completed by Lin Qi. Primary mouse brain samples were harvested from mice as after 
proper euthanasia and sacrifice procedures. Brains were preserved in formalin and 
paraffin-embedded for either sagittal or horizontal sectioning. Sections were 
deparaffinized, dehydrated, and stained according to standard protocol. The following 
primary antibodies (Dilution, Catalog number Company) were used: 
REST (1:50; #00141 Bethyl Labs) GFAP (1:50 3670 CST) 
Vimentin (1:200, ab92547 Abcam) CXCR4 (1:250 ab124824 Abcam) 
Laminin (1:200, ab11575 Abcam) SDF1 (1:100 MAB350 RnD Systems) 
TUBB3 (1:250 801201 Biolegend) Pax-6 (1:200, PRB-278P Biolegend)  
NeuN (1:200 ab13938 Abcam) LSD1 (1:200, ab Abcam) 
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p-ERK (1:200)  
 
Secondary rabbit and mouse antibodies in glycerol were obtained from Jackson 
Labs and used at 1:100. Slides were counterstained with hematoxylin. All samples were 
completed in triplicate. Positive controls using other normal mouse organs and internal 
controls were used where applicable.  
Western Blot 
Primary progenitor cell and human cell samples were lysed in RIPA buffer 
supplemented with protease and phosphatase inhibitors for 30 minutes with intermittent 
vortexing. Protein samples were subjected 4-12% sodium dodecyl sulfate-gradient gel 
electrophoresis and standard western blot protocol. Antibodies were diluted in TBS-T with 
0.05% milk. The following primary antibodies (Dilution, Catalog number Company) were 
used: 
REST (1:1000, Millipore 07-579) P-ERK (CST #9101) 
Vimentin (1:200, ab92547 Abcam) CXCR4 (1:250 ab124824 Abcam) 
Type III b-tubulin (Abcam 1:1000),  SDF1 (1:100 MAB350 RnD Systems) 
Actin (Abcam 1:50,000) Total ERK (CST #9102) 
H3K4-2me (Upstate 07-030) LSD1 (1:200, ab Abcam) 
H3K9-2me (Upstate 07-441)  
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Secondary antibodies against rabbit and mouse were purchased from Jackson labs, used 
at 1:100 dilution, and stored 1:1 in glycerol and stored at -20 degree Celsius. Blot 
development was completed using a Bio-Rad ChemiDoc imaging system. Volume 
densitometry was completed using the BioRad companion software. 
Quantitative Reverse Transcriptase Real-Time Polymerase Chain Reaction (qRT-
PCR) 
RNA was isolated from cells using Qiagen RNA mini-prep kits. cDNA was made 
from isolated RNA using iSCRIPT and qRT–PCR reactions were performed following 
standard protocol in 96-well plates using a Roche LightCycler 96 machine. Relative 
mRNA expression was calculated using the comparative ΔΔ-Ct (cycle threshold) method 
and was normalized using 18S expression.  
The following primer sequences were used (if prefaced with ‘m’, mouse; if prefaced with 
‘h’, human):  
mREST  f: CGCCGTCAGCAACGAGAAGAT  r: GCTTTAGTCTCCGCCGCCAC 
mCXCR4  f: CTGTAGAGC GAGTGTTGCC  r: CCAATCCATTGCCGACTA 
m18S  f: GCAATTATTCCCCATGAACG  r: GGCCTCACTAAACCATCCAA 
mSDF1  f: ACCAGTCAGCCTGAGCTACC  r: CCAGGTACTCTTGGATCCACT 
mGFAP  f: GATGTCTACCAGGCGGAGC  r: CTATACGCAGCCAGGTTGTTC 
mTUBB3  f: CCCTTCGATTCCCTGGTC  r: ACGGCACCATGTTCACAG 
hREST  f:GTAGGAGCAGAAGAGGCAGAT  r: GCTTCACGTTCTTCTACTGCT 
hCXCR4 
 
f:GGATCGTGTGTAGAGTGCAGTC 
 r: TCCCCATACTCGGCGTCTT 
h18S  f:CGGCGACGACCCATTCGAAC  r:GAATCGAACCCTGATTCCCCGTC 
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hSDF1  f: CCAATGTCTTGATGCATGC  r: AGGTACTGACATGTGAGGGAGC 
hBMP2 f: AACACTGTGCGCAGCTTC r: TTCGGTGATGGAAACTGCTA 
hHIF1A f: TGCTCATCAGTTGCCACTTC r: TCCTCACACGCAAATAGCTG 
Scratch Test (Would closure experiment) 
Human MB cells were plated in equal numbers in a 6-well plate. Cells were allowed 
to settle until confluent and wound was administered with a sterile tip. If applicable, drug 
was administered immediately following wound administration with a change of media. 
Images were taken of the scratch every 6 hours. Percent change of wound confluence 
was calculated using TimeScratch software developed by the Koumatkos group. Each 
well was compared to its own starting time point and measured as a percentage of 
confluence.  
Boyden Chamber 
24-well transwell Matrigel migration assay plates and control inserts were 
purchased from Corning (Catalog #354480). Briefly, approximately 2.5 x 104 cells were 
seeded in 8 uM pore-size transwell chambers. The bottom chamber was filled with 20% 
FBS or SDF1 to act as a chemoattractant. Cells were set to incubate for 22 hours and 
cells were fixed and dyed by Hemistat triple pack and imaged under a microscope. Cell 
nuclei were counted from 4x images were taken of the membrane insert. CellCounter 
software was used to automate the counting process. Cells were plated in triplicate and 
averaged. 
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Chapter 3:  
Analysis of cytoarchitectural defects 
in the cerebella of transgenic REST 
mice. 
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3.1 Characterization of defects 
Generation of the transgenic REST mouse model 
Previous studies, including our own, have implicated REST as a driver of MB 
progression and poor patient prognosis (47, 74). In order to investigate the specific 
contribution of REST to aggressive tumor behaviors, we generated a novel REST-
transgenic mouse (RESTTG) (Figure 1). Briefly, REST-NeuroD2 mice were crossed with 
Math1-cre mice to create a tamoxifen-inducible high-REST expressing mouse with 
specific upregulation of REST in the cerebellar granule cell compartment, the cell of origin 
for SHH group MBs (8, 31, 32). The NeuroD2 specification targets cells as they are 
entering the inner EGL of the cerebellum to begin the differentiation process. This 
promoter was chosen for specificity but also provides an interesting window to see what 
happens when REST is elevated ectopically in a cell that is programmed to differentiate 
with other mechanisms. RESTTG mice are tamoxifen induced from postnatal day 3-5 to 
induce REST expression in the Math1+/NeuroD2+ cellular compartment. 
Examination of postnatal survival of transgenic mice revealed that a subset of mice 
died within a few months. The cause of death of these mice is still under investigation and 
tumor development did not appear to contribute to mortality. The fact that REST 
expression in these mice did not result in generation of tumors is consistent with previous 
results concluding that multiple genetic “hits” are necessary to induce tumorigenesis, 
including MYC amplification or overexpression.  
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REST elevation disrupts normal cytoarchitecture in the postnatal cerebellum  
Careful analysis of the brains from RESTTG animals revealed a peculiar phenotype. 
Hematoxylin and eosin (H&E) staining of horizontal sections from RESTTG mice 
demonstrated the existence of asymmetric foliation defects in the cerebellum (Figure 12A-
C). 
To further investigate this, a mathematical equation was developed to quantify the 
symmetry between hemispheres. Normalization to hippocampal symmetry helps control 
for slicing error. The equation is as follows: 
𝑀𝑖𝑟𝑟𝑜𝑟 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒𝑠 =
(𝐴𝐶𝑏1 − 𝐴𝐻𝑃1)
𝐴𝐶𝑏1
−  
(𝐴𝐶𝑏2 − 𝐴𝐻𝑃2)
𝐴𝐶𝑏2
 
The conformity of the cerebella from RESTTG and wild-type (WT) animals were 
analyzed. Three out of the five cerebella from RESTTG mice had discernable foliation 
defects, and as a whole exhibited a two-fold increase in measured asymmetry. However, 
when two RESTTG animals with less conspicuously altered brains were excluded from the 
analysis, the asymmetry quotient became 3 to 4 times that of wild-type animals.  
To improve the field of view for migration defects and better examine cerebellar 
lamination, brains were cut in the sagittal plane for staining and analysis. Wild-type mice 
sections stained with H&E exhibited normal lamination into the external granule cell layer 
(EGL), molecular layer (ML), and internal granule cell layer (IGL). H&E staining of sagittal 
sections of RESTTG mice brains revealed several areas of perturbed cytoarchitecture with 
varying degrees of severity (Figure 13). 
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To determine if the defects in cerebellar cytoarchitecture of RESTTG mice were due 
to changes in cell migration, IHC analyses were performed using anti-REST and anti-
Vimentin antibodies. Stronger REST positivity was observed in the inner EGL cells in 
RESTTG mice compared to WT mice (Figure 13). Cells with higher REST expression in 
the EGL of RESTTG mice displayed an abnormal migration pattern and appeared to 
surround low-REST or REST-negative cells. Nests of cells with moderate cytoplasmic 
expression of REST were also seen in the cerebellar meningeal space of RESTTG mice, 
which were absent in WT mice. Vimentin immunostaining revealed disordered projections 
in cerebellar EGL sections where REST-high progenitors reside. Nests of cells with 
cytoplasmic REST expression were also highly Vimentin positive in the meninges. 
Together, these data capture the potential capacity of cellular REST expression to alter 
cell migration and agitate the postnatal cytoarchitecture of the cerebellum. 
REST elevation affects migration and organization of neuronal and glial cells 
IHC analyses were performed to determine the identity of the misplaced cells in 
the cerebella of RESTTG mice. Staining with an anti-laminin antibody was done to confirm 
the integrity of the basement membrane around the cerebellum and within the fissures 
between folia in WT mice (Figure 14). Interestingly, laminin staining of RESTTG mice 
revealed a disorganized inundation of the meninges into the cerebellar structure. The 
severity of basement membrane disorganization was consistent with the acuteness of the 
migration defect (Figure 14). 
Next, utilizing the RESTTG mouse hemagluttinin tag (HA), we observed HA-positive 
cells were found in the meningeal space invaginated within and around the cortex of 
RESTTG mice (Figure 15). While not all of these cells were HA-positive, cells within the 
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population have clear cytoplasmic staining. This results raises an interesting possibility 
that RESTTG GNPs may be herding or influencing the migration of other seemingly normal 
cells. Further, the leptomeningeal dissemination of these cells could have significant 
implications in tumor progression and metastasis. 
Cells of neuronal and glial origin are the most prominent players in cerebellar 
migration and development (10, 13, 22, 101). To ask if REST elevation disturbed 
migration of granule neural progenitors (GNPs) themselves, IHC analyses were 
performed using anti-NeuN, -beta-tubulin III (TUBB3), and –Pax-6 antibodies (for 
neuronal nuclei, projections, and GNPs respectively). We observed that misplaced cells 
were largely Pax-6 positive and negative for both NeuN and TUBB3, suggesting that 
these cells were indeed undifferentiated progenitors (Figure 16, Figure 17).  
Interestingly, staining for glial fibrillary acidic protein (GFAP) was diminished in 
areas with the most pronounced migration defects (Figure 16, Figure 17). It is well 
established that glia are vital to scaffolding GNPs in directed migration to the IGL (51-53). 
Consistent with this, staining against brain lipid-binding protein (BLBP), a marker for 
Bergmann glia, revealed that projections in these areas were disorganized as well (Figure 
16, Figure 17). There was no detectable staining for GFAP or BLBP in meningeal pockets 
of infiltration. These findings indicate that REST elevation in GNPs is associated with not 
only changes in GNP migration but also related to altered presence of glial cells and 
potentially their organization in the cerebellum. 
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Figure 11. Generation of transgenic REST mouse model. A) RESTTG mice were 
created by crossing a mouse expressing a human REST transgene driven by a 1 Kb 
region of the NeuroD2 promoter with a tamoxifen inducible Math1-CreER mouse. B) The 
transgene expression is based on Cre-lox method of recombination and is tagged with 
3HIS-3HA tag. PCR validated expression of the REST transgene. C) qPCR performed 
with primers against human REST demonstrated successful expression of the transgene 
in RESTTG mice but not WT mice. D) IHC of RESTTG animals show increased expression 
of REST protein in the EGL compared to WT. Data adapted from work done for another 
unpublished manuscript in the lab. Work and figure produced by Tara Dobson.   
A
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Figure 12. Horizontal brain slices taken from Wild-type and RESTTG mice. Horizontal 
sections were taken from postnatal 14 day old mice and analyzed for cerebellar 
symmetry. Brains from RESTTG mice appeared to display a midline shift. A) Panel of 
horizontal sections from WT and RESTTG mice. B) Example of increased magnification of 
asymmetry. C) Symmetry equation A=Area of, Hp=Hippocampus, Cb=Cerebellum (n=3, 
n=5; p<0.05).  
B
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Figure 13. REST elevation disrupts normal cytoarchitecture in the postnatal 
cerebellum. (A) Sagittal sections stained with H&E from p8 WT and RESTTG mice. (B) 
Vimentin and REST immunostaining of WT and RESTTG mice. (C) Lower magnification 
images of REST and Vimentin staining.  
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Figure 14. Laminin staining of basement membrane. A) Staining comparison of anti-
laminin showing compromised meningeal structure and inundation of basement 
membrane. B) Quantification of parenchymal laminin staining (n=3; *p<0.05;**p<0.01).  
B
. 
A
. 
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Figure 15. Pockets of expanded, ectopically placed cells contain HA-positive GNPs. 
Analysis of sagittal sections of WT and RESTTG mice revealed the existence of pockets 
of misplaced cells that contain hemagluttinin-positive cells in RESTTG mice.  
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Figure 16. REST elevation affects migration and organization of neuronal and glial 
cells. A) Representative images at 40x magnification of NeuN staining, TUBB3 staining 
and Pax-6 staining (n=3, top panel). B) Representative images at 40x magnification  of 
BLBP staining and GFAP staining of p8 WT EGL areas and RESTTG mice abnormal EGL 
areas (n=3, bottom panel). Black arrows point to areas of interest, misplaced cells in the 
parenchyma or meningeal space. 
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Figure 17. Alternative objectives: REST elevation affects migration and 
organization of neuronal and glial cells.  Representative images at A)10x magnification 
and B) 100x magnification of NeuN staining, TUBB3 staining, Pax-6 staining, BLBP 
staining, and GFAP staining of p8 WT EGL areas and RESTTG mice abnormal EGL areas 
(n=3). Black arrows point to areas of interest, misplaced cells in the parenchyma or 
meningeal space. 
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3.2 Identification and validation of crucial gene expression changes 
REST elevation increases CXCR4 activation and chemokinesis of granule cells to 
SDF1 
We next examined the mechanism by which REST influences GNP function and 
lineage specification. In order to search for candidates, RNA-sequencing of GNPs from 
WT and RESTTG mice was performed. Analysis of RNA-sequencing data using ingenuity 
pathway analysis revealed 572 significant differentially expressed genes (Figure 16). 
Pathway analysis of the RNA-sequencing data identified significant alteration of genes 
involved in cell. Surprisingly, a number migration related genes were downregulated in 
RESTTG mice compared to WT mice. (Figure 18).  
More careful analysis of the data illuminated a few crucial expression changes in 
molecular players of proper cerebellar lamination BDNF, CXCR4, and SDF1 (Figure 19). 
CXCR4 signaling is of critical importance to proper development of the cerebellar EGL 
and depletion of CXCR4 can lead to foliation defects associated with early radial migration 
(18, 39). 
Transcriptome comparisons between WT and RESTTG mice revealed a variable 5 
to 10 fold increase in REST gene expression. This elevation was associated with 
increased CXCR4 and SDF1 transcript expression, with the largest and most significant 
effect occurring in the animal with the highest REST (Figure 20). GNPs from these mice 
had reduced differentiation as shown by reduced beta-tubulin class III (TUBB3) 
expression and increased GFAP expression suggestive of retrograding lineage 
specification. REST repression of BDNF was confirmed in these GNPs as well.  
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When compared with WT GNPs at the protein level, GNPs from RESTTG mice had 
a 3 fold increase in CXCR4 protein and a 2 fold increase in SDF1 protein (Figure 21). 
Interestingly, while activation of downstream effector of CXCR4, phosphorylated ERK1/2, 
(p-ERK – normalized to total ERK) was increased 3 fold, total ERK 1/2 was also elevated 
2 fold (Figure 21). These changes appear to be post-transcriptionally as ERK 1 and ERK 
2 levels are not similarly increased at the transcript level. A two-fold increase in 
expression of vimentin is seen in GNPs from RESTTG mice, indicating changes in GNP 
motility in response to REST protein upregulation. 
In line with increased expression of CXCR4 protein, GNPs from RESTTG mice 
exhibited a 3-fold increase in migration to SDF1 as compared to GNPs from WT mice 
(Figure 21).  
IHC of cerebella from RESTTG mice revealed moderate staining of CXCR4 with 
less organized patterning in the parenchyma compared to sections from WT mice (Figure 
22, 23). Indeed, CXCR4 staining was very dense in RESTTG mice in areas of GNP 
expansion near the meningeal barrier. Compared to WT samples, SDF1 immunostaining 
was also increased in RESTTG mice, especially in cell pockets of expanded meningeal 
space (Figure 22).  
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Figure 18. RNA sequencing of GNPs from WT and RESTTG mice. RNA sequencing of 
GNPs from WT and RESTTG mice was completed by Active Motif (Carlsbad, CA). 
Functional analysis revealed several significantly changed functions including cancer, 
cellular movement, and development. A) Volcano plot of significantly altered gene 
expression (green dots = p<0.05; red dots = q<0.05). B) Ingenuity Pathway Analysis 
functional analysis.   
A
. 
B
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Figure 19. RNA-sequencing alignments with CXCR4, SDF1, and BDNF genes. 
Integrative genome viewer (IGV) alignment of RNA-sequencing data with CXCR4, SDF1, 
and BDNF genes revealed that GNPs from RESTTG mice altered the expression of these 
lamination-important genes.    
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Figure 20. Differential transcript expression of GNPs from RESTTG mice. GNPs from 
WT and RESTTG cells were analyzed for transcript levels of REST, CXCR4, ERK1, ERK 
2, SDF1, BDNF, TUBB3, and GFAP. All transcripts were normalized to 18S and then WT 
gene expression. (n=3; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).   
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Figure 21. Differential protein expression and chemokinetic activity of GNPs from 
RESTTG mice. A) GNPs from WT and RESTTG cells were subjected to western blot to 
assess protein levels of REST (band at ~120 kDa), CXCR4 (band at ~40 kDa), 
phosphorylated ERK (p-ERK, band at ~42 kDa), total ERK (band at ~42 kDa), SDF1 
(band at ~30 kDa), and vimentin (band at ~54 kDa). Total H3 served as a loading control 
(band at ~20 kDa). B) Quantification of blot (n=3; *p<0.05, **p<0.01). C) Migration of 
GNPs from RESTTG mice was significantly 3-fold higher than progenitors from WT mice 
(n=3; p<0.05). D) Transcript of ERK1/2 was minorly but significantly altered by REST 
elevation in GNPs.  
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Figure 22. Immunohistochemistry of CXCR4 and SDF1 in sagittal brain sections 
from WT and RESTTG mice. Representative images at 40x magnification of 
immunostaining of CXCR4 and SDF1 which is increased in areas of meningeal 
invagination and ectopically placed cells.  
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Figure 23. Alternative objectives: Immunohistochemistry of CXCR4 and SDF1 in 
sagittal brain sections from WT and RESTTG mice. A) Representative images at 10x 
and 100x magnification of immunostaining of CXCR4 and B) SDF1.  
  
A
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In summary, this chapter has focused on describing how postnatal induction of 
REST expression perturbs postnatal cerebellar development. We observed that REST 
expression alone did not induce tumor formation. However, REST expression in the GNP 
compartment did alter the normal cerebellar cytoarchitecture. These abnormalities were 
observed in the GNP compartment and the glial compartment and were accompanied by 
an altered laminin/basement membrane structure. Molecular analysis of GNPs with 
transgenic REST expression revealed a number of differentially expressed genes. Among 
them were genes of critical importance to proper cerebellar lamination, including BDNF, 
SDF1 and CXCR4. As BDNF is a known REST target, we focused on CXCR4 – a novel 
interaction for REST. REST increased CXCR4 expression at the protein and transcript 
level, however changes at the protein level were more significant and consistent. 
Furthermore, GNPs from RESTTG mice exhibited a significantly stronger response to the 
CXCR4 ligand, SDF1, as measured by elevated downstream ERK signaling. Taken all 
together, the results from chapter 1 suggest that REST is capable of perturbing the 
CXCR4 signaling axis to regulate mobility of GNPs during neuronal maturation. A 
graphical summary of the results and their interpretation is shown in figure 24. 
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Figure 24. Graphical summary of chapter 3. Overexpression of REST in cerebellar 
GNPs results in abnormal cytoarchitecture of the cerebellum. Normal cerebellar 
lamination is ensured by temporal expression of CXCR4 in the GNPs of the outer EGL. 
These cells migrate tangentially to SDF1 secreted by meningeal cells. As cell begin the 
differentiation process, cell responsiveness to CXCR4 stimulation is blocked (EphrinB2 
expression is postulated to play a role in this) and cells begin responding to glia-
associated radial migration cues. GNPs finish their migration by performing glia-
independent migration past the PL, to their final destination in the IGL where they become 
mature granule neurons with projections spanning from the EGL to the internal white 
matter tract. In our RESTTG model of abnormal cerebellar development, elevated CXCR4 
expression in GNP cells may be responding to disorganized SDF1 secretion in the EGL 
resulting in an abnormal retention of GNPs in the EGL. This retention would be 
strengthened by blocked radial migration mechanisms (BDNF, EphB2, and glial 
organization) leading to increased proliferation and tangential migration in the outer EGL. 
EGL – external granule cell layer; ML – molecular layer; PL – Purkinje layer; IGL – internal 
granule layer; SDF1 (green dots)– stromal derived factor 1; BDNF (pink dots)- brain 
derived neurotrophic factor 1;  
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Chapter 4:  
REST and SHH signaling 
cooperatively upregulate CXCR4 in 
disseminated MB   
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4.1 Sonic hedgehog medulloblastoma mouse models in vivo 
It is established that REST expression can promote MB growth, progression, and 
aggressive disease course. It is also established that CXCR4 expression is related to 
metastasis and worsened patient prognosis. This effect is especially prominent in patients 
with SHH MB. However, the cooperation of REST and CXCR4 in the context of cancer 
has not been reported previously. The results of the experiments in RESTTG mice 
described in the previous chapter suggest that REST increases CXCR4 expression and 
chemotactic responsiveness to SDF1. However, whether or not these mechanisms can 
operate in the context of MB are unknown. 
The identification of GNPs as the cell of origin of SHH MB and the availability of 
transgenic mouse models has advanced our understanding of molecular mechanisms 
driving tumor behaviors in the context of SHH hyperactivity. Further, REST is a 
demonstrated driver of aggressive tumor behaviors in SHH MB but the mechanisms of 
how REST promotes tumor dissemination are still being investigated. We propose that 
REST and the SHH pathway cooperatively upregulate CXCR4 signaling, which is known 
to drive MB dissemination and metastasis. To investigate this, we utilized our transgenic 
REST mouse model along with a popular mouse model of SHH MB (Ptch+/-). This mouse 
lack an allele for the PTCH1 receptor. This deregulates the SMO receptor and allows for 
increased SHH signaling through Gli activator transcription factors. This Ptch+/- mouse 
was crossed with our RESTTG mouse to create a mouse with high levels of REST in the 
context of constitutive SHH activation (RESTTG/Ptch+/-). Tumors from these mice were 
immunohistochemically examined for CXCR4 expression and downstream activity.  
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REST elevation in the context of constitutive SHH signaling enhances CXCR4 
signaling  
Work from other groups has previously established that mice with tumors 
stemming from constitutive SHH activity in GNPs had elevated CXCR4 expression (39, 
42, (80-82). Mechanisms for upregulation of CXCR4 have been demonstrated to be due 
to loss-of-function mutations in negative regulators of CXCR4 like G protein-coupled 
receptor kinase 5 and 6 (GRK5/6) (83). GRK5/6 is a kinase with downstream activity that 
helps internalize CXCR4. It is already established that GRK5/6 is inhibited by an 
oncogene named WIP1 (84). However, analysis of our RNA-sequencing data did not 
reveal any significant differences in GRK5/6 or WIP1 transcript expression between WT 
and RESTTG mice. However, we cannot exclude changes in protein levels. 
Having found that REST elevation increased CXCR4 expression and signaling, we 
aimed to determine if this REST-dependent amplification would increase tumor 
dissemination. As described in the previous chapter, RESTTG mice do not form tumors, 
but exhibit defects in GNP migration and cerebellar architecture. Ptch+/- mice do develop 
tumors by 6-9 months and at a frequency of 15-20%. Interestingly, REST elevation in the 
context of Ptch haploinsufficiency (RESTTG/Ptch+/-) caused tumor formation in 100% of 
the mice between 10-90 days. Survival of Ptch+/- and RESTTG/Ptch+/- mice revealed that 
RESTTG/Ptch+/- mice had drastically reduced survival compared to Ptch +/- mice (Figure 
25). Importantly, while there was no overt evidence of spinal metastasis, tumors from 
these mice exhibited highly infiltrative disease compared to the localized tumors in Ptch+/- 
mice.  
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To examine the activity of the CXCR4 signaling cascade in this SHH tumor 
environment, Ptch+/- and RESTTG/Ptch+/- mice were sacrificed after significant 
symptoms of tumor burden were exhibited (representative images were taken from mice 
sacrificed at ages day 45 and day 239, respectively). IHC analyses of RESTTG/Ptch+/- 
tumor samples revealed increased REST and Vimentin staining density compared to 
Ptch+/- tumors (Figure 26, Figure 28). CXCR4 and SDF1 staining was also elevated in 
RESTTG/Ptch+/- tumors (Figure 27, Figure 28). While both tumors were CXCR4 positive, 
RESTTG/Ptch+/- tumors exhibited substantially increased CXCR4 positivity, especially 
around areas of meningeal invagination (Figure 27, Figure 28). Immunostaining of 
downstream effector of CXCR4 signaling, p-ERK, was more pronounced in the 
RESTTG/Ptch+/- tumor samples (Figure 27, Figure 28). BDNF staining revealed 
heterogenous expression in Ptch+/- tumors but was largely undetectable in 
RESTTG/Ptch+/- tumors (Figure 26, Figure 28). 
 Overall, these histological analyses show that REST and SHH signaling cooperate 
in decreased BDNF and increased CXCR4/SDF1 levels and enhanced signaling through 
the CXCR4 receptor. These immunostaining patterns are correlated with dramatically 
reduced survival and leptomeningeal dissemination. 
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Figure 25. Survival curve analysis of Ptch+/- and RESTTG/Ptch+/- mice. A) 
RESTTG/Ptch+/- mice were generated by crossing RESTTG with Ptch+/- mice. B) Survival 
of RESTTG/Ptch+/- mice was drastically reduced compared to WT and Ptch+/- mice and 
C) tumor burden was larger. D) H&E staining of tumors from RESTTG/Ptch+/- mice 
showed that these tumors had rougher tumor edges indicative of more infiltrative tumors. 
Figure adapted from manuscript currently under review describing REST deregulation of 
SHH signaling. Work and figure produced by Tara Dobson and Rong-Hua Tao. 
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 Figure 26. 40x images of immunohistochemistry of REST, Vimentin, and BDNF in 
MB tumors from Ptch+/- and RESTTG mice. A) Representative images at 40x 
magnification of REST, Vimentin, and BDNF immunostaining in Ptch +/- (n=4) and 
RESTTG/Ptch+/- (n=3) tumors. B) Quantification of staining density was completed under 
blinded conditions. Five fields of 40x images per tumor were taken for analysis. 
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Figure 27. 40x images of immunohistochemistry of CXCR4, SDF1, and p-ERK in MB 
tumors from Ptch+/- and RESTTG mice. A) Representative images at 40x magnification 
of CXCR4, SDF1, and phosphorylated-ERK1/2 (p42/44) immunostaining in Ptch +/- (n=4) 
and RESTTG/Ptch+/- (n=3) tumors. B) Quantification of staining density was completed 
under blinded conditions. Five fields of 40x images per tumor were taken for analysis.  
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Figure 28. 4x and 10x images of immunohistochemistry of MB tumors from Ptch+/- 
and RESTTG mice. REST elevation in the context of constitutive SHH signaling enhances 
CXCR4 signaling. A) Representative images at 4x and 10x magnification of REST, 
Vimentin, and BDNF immunostaining of Ptch+/- and RESTTG/ Ptch+/- tumors. B) 
Representative images at 4x and 10x magnification of CXCR4, SDF1, C) phosphorylated-
ERK1/2 (p42/44) and BDNF immunostaining of tumors.   
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4.2 Human medulloblastoma patient data 
Validation of REST-CXCR4 connection in SHH MB patient samples 
In order to validate the clinical relevance of the REST-dependent elevation on 
CXCR4, we examined publicly available MB patient data sets provided by the St. Judes 
Legacy Genomes Project (NIH GSE34217 and the National Institute of Health (NIH 
GSE85217) (7).  
Interestingly, primary analysis of patient samples from the St. Judes dataset found 
that expression of REST expression did not significantly differ between groups (Figure 
29). However, a negative post-transcriptional regulator of REST, beta-TRCP, was lowest 
in SHH MB. Further, expression of beta-TRCP’s complex member, S-phase kinase-
associated protein 1 (SKP1), was also very low in SHH. The downregulation of these 
essential components of the SCP (SKP1-CUL1-F-box protein) ubiquitin ligase complex 
members suggest that stabilization of REST protein is potentially increased in these 
patients. This was associated with an increase in CXCR4 expression in SHH MB (Figure 
30).  
These were some preliminary results suggesting that REST and CXCR4 may have 
a cooperative relationship in SHH MBs, especially.  
In the Cavalli et al datasets, we found that REST and CXCR4 expression was 
significantly correlated across all 763 MB patient samples (Figure 31). Examination of 
correlations between REST and CXCR4 expression across MB molecular subgroups 
uncovered a subgroup-dependent effect of correlation (Figure 32). The WNT subgroup of 
MB had a negative but insignificant correlation between REST and CXCR4 transcript 
78 
 
expression. Groups 3 and 4 had significant positive correlations between REST and 
CXCR4 transcript expression with correlation coefficients of r=.25 and r=.36 respectively.  
Interestingly, despite the description of CXCR4 upregulation in SHH MB mouse 
models, we failed to observe a significant correlation between REST and CXCR4 across 
SHH MB subgroups. However, closer analysis based on the newly reported 
subclassification of SHH MBs into α, ß, Γ, and δ identified strong and significant 
correlation coefficients of r=.42 in SHH ß and r=.46 in SHH δ subtypes. Out of these two 
groups, SHH ß patients had the highest levels of REST and CXCR4 and also had a 
significant correlation with CXCR4 ligand, SDF1 (data not shown). 
Division of SHH MB patient samples based on REST and CXCR4 expression 
Focusing on the SHH subgroup, we put the patient samples into four conditions, 
based on REST and CXCR4 expression (Figure 33).  The conditions were determined as 
follows: REST and CXCR4 transcript expression both being higher than average (both 
high), REST transcript expression being lower than average and CXCR4 transcript 
expression being higher than average (REST low, CXCR4 high), REST transcript 
expression being higher than average and CXCR4 transcript expression being lower than 
average (REST high, CXCR4 low), and REST and CXCR4 transcript expression both 
being lower than average (both low). 
When we examined patient outcomes based on these conditions, we observed the 
majority of patients with metastasis within the SHH- β and δ groups had high transcript 
expression of both REST and CXCR4 (Figure 33). 100% of patients with metastasis in 
the SHH β subtype had high REST levels, and 90% of those patients expressed high 
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CXCR4 concurrently. SHH β patients are characterized by a predominantly infantile age, 
metastasis, and poor prognosis (Figure 3). 
Examination of overall survival across the whole SHH cohort did not reveal any 
differences between both high and both low groups (Figure 34). However within the SHH-
beta group, there was a large but insignificant difference in the survival curve likely due 
to insufficient patient data in these groups.  
These results are the first to implicate the importance of REST and CXCR4 
cooperativity in poor patient outcomes. These results seem to be specifically relevant in 
patients in the SHH ß subgroup, mostly infantile patients with metastatic disease.   
Examination of patient derived orthotopic xenografts (PDOX) for REST-associated 
CXCR4 expression and signaling 
To further examine the effect of REST elevation on CXCR4 expression and 
signaling, we obtained samples from Patient-Derived Orthotopic Xenograft (PDOX) 
models of SHH MB (Figure 35). PDOX samples were immunohistochemically analyzed 
for REST and CXCR4 expression and activation. PDOXs were labelled either low-REST 
or high-REST based on levels of REST expression (Figure 36, Figure 37). BDNF was not 
detectable in Low- or High-REST tumors. Vimentin positivity was observed in low-REST 
tumors to be along the tumor boundary, whereas that in high-REST tumors included the 
parenchyma as well. CXCR4 and phosphor-ERK1/2 staining was directly correlated with 
REST levels in these tumors and SDF1 expression was present in cells infiltrating the 
surrounding parenchyma. 
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 These results further support that REST elevation contributes to an increase of 
CXCR4 levels and enhanced ERK1/2 phosphorylation in SHH sub group murine and 
human MBs. 
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St. Judes Legacy Genome Project expression of REST, B-TRCP, and SKP1.  
Transcript expression of A) REST B) B-TRCP and C) SKP1 across MB subgroups from 
the St. Judes Genome Project 2016. The x-axis of these graphs contains z-scores for 
REST, BTRC, and SKP1 transcript probes.
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Figure 30. St. Judes Legacy Genome Project expression of REST, CXCR4, and 
SDF1. Transcript expression of A) REST B) CXCR4 and C) SDF1 across MB subgroups 
from the St. Judes Genome Project 2016. The x-axis of these graphs contains z-scores 
for REST, CXCR4, and SDF1 transcript probes.   
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Figure 31. REST and CXCR4 transcript correlation across all MB. A) Expression of 
REST and CXCR4 are positively correlated across 763 MB patient samples.  C) This 
Cavalli et al, 2017 dataset was the first to subtype WNT, SHH, Group 3, and Group 4 MB 
into α, ß, Γ, and δ.  
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Figure 32. Subgroup specific correlation of REST and CXCR4 transcript 
expression. A) Correlations of REST and CXCR4 transcript expression in the MB 
subgroups. Significant correlations were observed in Group 3 and Group 4 MB. B) Further 
analysis of SHH subgroups revealed that REST and CXCR4 are strongly correlated in 
SHH ß and δ groups.   
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Figure 33. Classification of REST and CXCR4 expression and SHH MB patient 
metastasis. A) SHH MB samples were stratified into groups based on CXCR4 and REST 
expression patterns. B) Analysis of patients with metastasis in SHH subtypes revealed 
that 100% of patients with metastasis in the SHH ß subtype had high REST and ~90% of 
the same patients had CXCR4 co-elevated. The majority of patients in both α and δ also 
had high REST and high CXCR4 expression.  
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Figure 34.  Survival of SHH patients with high or low REST/CXCR4 expression. A) 
A) Kaplan-Meier survival curves of patients from high and low REST and CXCR4 tumor 
transcript expression across all SHH patients and B) SHH-beta patients.  
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Figure 35. Schematic of patient-derived orthotopic xenografts procedure. These 
experiments were done by collaborator Xiao-nan Li at Texas Children’s Hospital. Tumor 
cells from patient tumors were cultured and injected orthotopically in mice. Cells that 
established tumors were passaged through inoculation of mice.  
91 
 
  
B 
A 
92 
 
 Figure 36.  40x objectives of low-REST and high-REST patient-derived orthotopic 
xenografts (PDOX). Respective images at 40x magnification of IHC of low-REST and 
high-REST PDOX samples. Immunostaining of A) REST, Vimentin, BDNF, B) CXCR4, 
SDF1, and p-ERK was completed.  
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Figure 37.  Alternative objectives: low-REST and high-REST patient-derived 
orthotopic xenografts (PDOX). Respective images at 10x magnification of IHC of low-
REST and high-REST PDOX samples. Immunostaining of REST, Vimentin, BDNF, 
CXCR4, SDF1, and p-ERK was completed.  
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4.3 Human medulloblastoma cell lines in vitro 
Examination of orthotopic xenografts for REST-associated CXCR4 expression and 
signaling using Daoy cells engineered with REST transgene 
In similar xenograft experiment, Daoy MB cells were transduced with a REST 
transgene (Daoy-REST) tagged with green fluorescent protein (GFP) and firefly luciferase 
(FFLUC) or a control vector with GFP and FFLUC. Daoy-REST and control Daoy cells 
were injected orthotopically into the cerebella of immunodeficient mice and tumor 
establishment was verified using bioluminescence imaging (BLI) (Figure 38). Mice were 
sacrificed at day 60 and tumor differences were examined.  
Consistent with previous experiments, we found increased tumor burden in mice 
injected with Daoy-REST cells (data not shown). Compared to Daoy tumors, tumors 
established with Daoy-REST cells were highly infiltrative and had higher number of 
invasive cell nodes in the surrounding parenchyma (Figure 39). 
 Daoy-REST xenografts also promoted the presence of extracranial tumors that 
had spread into and outside of the skull (Figure 39). Both Daoy and Daoy-REST tumors 
exhibited similar staining density of Vimentin (Figure 40). However, samples from Daoy-
REST xenografts displayed areas of vimentin positive projections that extended through 
the normal parenchyma and connected the primary tumor with disseminated nodes of 
Daoy-REST cells. As expected, Daoy-REST tumors had higher REST expression than 
Daoy tumors. Interestingly, extracranial tumors arising from Daoy-REST cells had 
elevated levels of REST compared to the intracranial tumor, suggesting that the more 
motile cells had increased REST.  
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Further, Daoy-REST tumors had higher amounts of CXCR4 expression than Daoy 
tumors, the highest levels being in the extracranial tumors of the Daoy-REST injected 
mice (Figure 41). Examination of downstream marker phosphorylated ERK1/2 revealed 
increased levels of signaling in both Daoy-REST tumor populations. Finally, BDNF was 
not detectable in Daoy or Daoy-REST tumors (Figure 40).  
REST elevation and increased migration is recapitulated in MB cells in vitro and 
blocked by CXCR4 antagonism 
To more directly assess changes in migratory capacity in response to REST 
elevation, in vitro scratch tests and transwell migration assays were performed using an 
isogenic cell pairs of human SHH MB, UW228/UW228-REST and Daoy/Daoy-REST. 
Daoy-REST and UW228-REST cells exhibited about a two-fold increase in migration as 
measured by scratch test compared to their isogenic counterpart (Figure 42). This was 
recapitulated in transwell migration assay, where UW228-REST and Daoy-REST cells 
migrated to 20% FBS twice as much as UW228 and Daoy cells respectively (Figure 43).  
Functional and pathway analysis of RNA-sequencing data from isogenic cell pair 
Daoy and Daoy-REST revealed similar changes in gene expression compared to RNA-
sequencing of GNPs from WT and RESTTG mice (Figure 44). Top functions related to 
increased REST expression included cancer, cell movement and adhesion, and 
development. Pathway analysis included a significant positive predicted z-score relating 
to increased CXCR4 signaling (Figure 45). 
Western blot analyses confirmed a 2.10 fold increase in CXCR4 protein in UW228-
REST UW228 (Figure 46).  However, SDF1 levels were decreased in UW228-REST cells. 
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Phosphorylation of ERK1/2 was slightly increased by 1.23 fold in UW228-REST cells and 
a similarly small REST-dependent 1.20 fold change in total ERK levels was also 
observed. BDNF was undetectable in our hands (data not shown). These experiments 
were also carried out in Daoy and Daoy-REST cells, which already had elevated levels 
of CXCR4 and REST. 
To examine if CXCR4 hyperactivity contributed to REST-dependent increases in 
migration, we treated UW228 and UW228-REST cells with the CXCR4 antagonist 
AMD3100 before subjecting them to a transwell migration assay with SDF1 as the 
chemoattractant. Untreated UW228-REST cells migrated almost two-fold more than 
UW228 cells on average, but did not reach significance. AMD3100 treatment caused a 
significant decrease in migration of UW228-REST cells and, although not significant, also 
reduced the migration of UW228 cells (Figure 47). AMD3100 also blocked the REST-
dependent advantage in migration seen by Daoy-REST cells in a standard transwell 
migration assay, while Daoy cells remained largely unaffected (Figure 48). These results 
suggest that AMD3100 is blocking SDF1-mediated chemokinesis through CXCR4. 
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Figure 38.  Schematic of Daoy/Daoy-REST orthotopic xenograft procedure. The in 
vivo work for these experiments were completed under the guidance and with the help of 
lab members, Bridget Kennis and Shavali Shaik. Daoy and Daoy-REST MB cell lines 
were cultured and injected orthotopically in mice. Tumor establishment and growth was 
monitored using bioluminescence imaging.  
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Figure 39.  Hematoxylin and Eosin staining of Daoy and Daoy-REST xenografts. 
Mice injected with Daoy-REST cells developed large tumor burden and extracranial 
tumors. H&E staining of sections of tumors from xenograft experiments allow for 
visualization of the tumor. Tumors established with Daoy-REST cells have rough tumor 
edges and a higher number of invasive nodes (black arrows). 
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Figure 40.  Immunohistochemistry of REST, Vimentin, and BDNF in Daoy and Daoy-
REST xenografts. Representative images of 10x and 40x magnification of 
immunostaining of REST, Vimentin, BDNF in Daoy and Daoy-REST xenografts.  
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Figure 41.  Immunohistochemistry of CXCR4, SDF1, and p-ERK in Daoy and Daoy-
REST xenografts. Representative images of 10x and 40x magnification of 
immunostaining of CXCR4, SDF1, AND p-ERK in Daoy and Daoy-REST xenografts.   
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Figure 42. REST transgene increases wound healing migration of SHH MB cell 
lines, UW228 and Daoy. UW228 and Daoy cells with and without REST transgene 
expression were subjected to scratch wound migration assay. Cells expressing REST 
transgene demonstrated 2-fold increase in migration (n=3; *p<0.05).  
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Figure 43. REST transgene increases transwell migration of SHH MB cell lines, 
UW228 and Daoy. A) Isogenic cell pairs of UW228 and Daoy cells were subjected to 
transwell migration assay. Cells expressing REST transgene demonstrated a near 2-fold 
increase in migration (n=3; *p<0.05). B) Invasion index normalizing cells to proliferating 
cells in the top chamber reveal a near two-fold increase in invasive capacity. C) Daoy-
REST cells migrated significantly more than Daoy cells over time. 
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Figure 44. Functional analysis of RNA-sequencing data from Daoy and Daoy-REST. 
Ingenuity pathway analysis of RNA-sequencing data revealed several significantly altered 
functions between Daoy and Daoy-REST. The top 26 significant functions are 
represented here.  
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Figure 45. Pathway analysis of RNA-sequencing data from Daoy and Daoy-REST 
cells. Ingenuity pathway analysis of RNA-sequencing data revealed several significantly 
altered signaling pathways between Daoy and Daoy-REST. Six of the top pathways of 
interest are represented here. CXCR4 signaling was predicted to be significantly 
increased in response to REST expression. 
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Figure 46. Isogenic cell pairs western blots. Cell lysates from isogenic cell pairs 
demonstrate a slight increase in CXCR4, SDF1, and p-ERK. Calcium-sensing protein 
Calmodulin (Calm) was also increased in UW228-REST but not Daoy-REST lysates. 
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Figure 47. REST-induced increase in chemokinesis to SDF1 is reduced by CXCR4 
receptor antagonism in UW228 cells. Chemokinesis to 100 ng/mL of SDF1 was 
increased in UW228-REST cells compared to UW228, with a trend reaching significance 
(n=3). Migration of cells to SDF1 was blocked by administration of 2.76 uM of CXCR4 
antagonist, AMD3100. 
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Figure 48. REST-induced increase in chemokinesis to SDF1 is reduced by CXCR4 
receptor antagonism in Daoy cells. Chemokinesis to 100 ng/mL of SDF1 was 
significantly increased in Daoy-REST cells compared to Daoy (n=3; *p<0.05). The 
advantage of REST given to the migration of cells to SDF1 was blocked by administration 
of 2.76 uM of CXCR4 antagonist, AMD3100. However, this reduction did not completely 
abolish the cell migratory response to SDF1, suggesting that the cell could still respond 
without CXCR4. Scratch wound migration revealed no significant differences in migration 
between treated and untreated cells at 24 hours post-wound. 
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 In summary, these results highlight the ability of REST to upregulate CXCR4 and 
promote signaling through the CXCR4 and SDF1 axis in the context of SHH MB. This is 
associated with leptomeningeal dissemination and reduced survival and larger tumor 
burden in our mouse models. 
 In patient samples, CXCR4 and REST are correlated in patients with metastasis 
and that patient-derived tumor samples with high-REST also display high levels of 
CXCR4 immunostaining compared to low-REST tumors. In xenograft mouse models 
with MB cell line Daoy, it is demonstrated that REST-transgene expression increases 
tumor dissemination and marker of invasive cells, vimentin. We also examine these 
cells in vitro and verify that REST transgene expression results in increased CXCR4 
expression and downstream signaling. Further, the migration advantage to SDF1 given 
by the REST-transgene can be blocked by administration of CXCR4 antagonist, 
AMD3100. 
 These model of our hypothesis based on chapters 1 and 2 is referenced in figure 
49. 
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Figure 49. Summary of hypothesis from chapters 1 and 2. REST increases the protein 
expression of CXCR4 to influence perturbation of GNP migration and cerebellar 
lamination and also cooperates with CXCR4 to increase tumor cell migration. REST also 
represses BDNF which has a demonstrated capability to negatively influence CXCR4.  
  
112 
 
 
 
 
 
Chapter 5:  
Targeting REST-LSD1 activity in 
medulloblastoma   
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5.1 Analysis of patient data 
Elevated levels of LSD1 are related to reduced survival of medulloblastoma 
patients. 
Since the discovery of LSD1 as a potential target in MB in 2013, little follow-up has 
been completed clarifying the role that LSD1 plays in MB development. Previous 
experiments demonstrated that LSD1 expression is increased in MB tumors over normal 
cerebellum. The authors found no difference in expression between subgroups. This was 
surprising as it is suggested by examination of patient data that the relevance of LSD1 
could be most important in patients with SHH and group 3 MBs. Tumors from these 
patients have drastic perturbations in H3K4 methylation consistent with overactive LSD1 
activity (79). While previous experiments have found no difference in expression levels of 
LSD1 in SHH or Group 3 tumors over other subgroups, enzyme activity is harder to 
quantify. Further, previous studies failed to examine patient outcomes including overall 
survival and metastasis related to LSD1 expression. 
In this chapter, we analyzed a large, publicly available patient dataset and 
examined patient outcomes related to LSD1 transcript expression. We also cluster SHH 
MB subgroups based on published LSD1 targets to examine predicted LSD1 activity. In 
subsets of SHH patients, mostly in the alpha subgroup, we find that patients have high 
LSD1 levels in conjunction with high cofactor REST expression and protein 
deubiquitylase USP7. Contrasting this cluster with an opposite aligning cluster revealed 
significant differences in patient survival. Further, we found that high REST increases the 
viability and migration of cells, consistent with previous reports. Genetic knockdown of 
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LSD1 was sufficient to block SHH MB cell growth, even in the presence of elevated REST. 
However, pharmacological inhibition of LSD1 had no effect on cell growth in these cell 
lines but did have REST-dependent effect on cell migration. In line with this, we find that 
irreversible LSD1 inhibition did not restore BMP2 gene expression in the way that genetic 
knockdown did. However, REST target HIF1A upregulation was reduced by irreversible 
LSD1 inhibition. These findings provide novel evidence for the differential role of LSD1 in 
the context of REST in invasive MB and provide a new molecular target for the REST-
LSD1 cofactor complex. 
Division of patient samples into high, moderate, and low expression of LSD1 
revealed an effect of LSD1 expression overall survival in MB patients. Divisions were 
made as follows: low (Z-score < -0.40), moderate (0.40 > Z-score > -0.40), and high (Z-
score > 0.40). These groups are arbitrary however, as the dataset from GSE85217 has 
no normal tissue control and it is already established that LSD1 expression is elevated in 
comparison to normal tissue.  
Patient outcomes across all MB related to LSD1 transcript expression. 
It has been previously established that LSD1 transcript and protein expression is 
elevated in MB tumor tissue compared to normal tissue (78). This study also found no 
differences in LSD1 transcript expression between subgroups. However, analysis of a 
publicly available dataset (GSE85217) of 763 MB tumor samples revealed a significant 
analysis of variance in LSD1 transcript expression (p<0.0001; Figure 50). Within this 
dataset, Group 4 MB samples were significantly lower than the other 3 subgroups. There 
were no significant differences between WNT, SHH, or Group 3.  
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Further, previous study did not look at patient outcomes associated with LSD1 
expression. Analysis of Kaplan-Meier curves revealed early survival differences in 
patients with low and high LSD1 levels (Figure 51). Interestingly, Mantel-Cox analysis of 
survival revealed a significant difference between low and moderate LSD1 across all of 
the MB patients (Figure 51). Subgroup specific analysis of overall survival related to LSD1 
expression found that Group 3 MBs had the most significant survival curve differences 
related to LSD1 expression (Figure 52). Surprisingly, the SHH subgroup did not have a 
significant curve difference despite previous studies noting that both SHH and Group 3 
tumors are characterized by demethylated histone 3 lysine residue 4 (H3K4) (Figure 53). 
However, the SHH subgroup did have the most variable LSD1 expression range with 
outliers on both the low and high spectrum. For these reasons, deeper analysis of the 
SHH subgroup was required. 
While there was no significant difference of overall LSD1 expression between 
patients with and without metastasis, the available patient data for these patients was not 
bountiful (Figure 54). Further, examination of LSD1 expression within patients with 
metastasis revealed that the majority of patients with metastatic MB had either moderate 
or high LSD1 expression (Figure 55). 
 In order to examine the potential of the tumors for epithelial to mesenchymal 
transition (EMT), we analyzed the expression levels of e-cadherin and vimentin (85). MB 
tumor dissemination and EMT is marked by an increase in expression of the filament 
protein, vimentin, along with the suppression of the cell adhesion molecule, e-cadherin. 
Analysis of patient samples with LSD1, saw a modest but significant positive correlation 
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with vimentin and negative correlation with e-cadherin (Figure 55). Together, these results 
suggest LSD1 may be involved in poor patient prognosis.  
While these results are interesting, there are limitations to this dataset as it only 
contains transcript data and the importance of protein stabilization and activity is 
paramount to epigenetic activity of enzymes like LSD1. Due to this, analysis of stabilizers 
of LSD1 and REST (like USP7, Skp1, and BTRCP) can give more information on 
predicted protein availability and activity (71, (86))(Figure 29). 
Analysis of LSD1 target gene clustering in SHH MB 
To ask if LSD1 co-elevation with other genes or perturbation of LSD1 activity in 
SHH tumors may have more predictive value, we performed clustering analysis using a 
cohort of 91 LSD1 target genes, USP7-a gene controlling LSD1 and REST protein 
stability and 8 REST and metastasis related genes in the brain. Interestingly, analysis of 
clustering data revealed the existence of 6 clusters that aligned with the subtypes 
published previously by Cavalli et al (Figure 56) (7). The composition of the clusters was 
as follows: Cluster 1 -80% of SHH δ tumors, clusters 2 and 3 - 67% of SHH α tumors 
individually and together added up of 78% SHH α tumors, cluster 4 - 92% SHH ß tumors, 
cluster 5 - 96% SHH Γ tumors, and cluster 6 was more undefined (Figure 57). 
Interestingly, cluster 2 (subset of SHH α tumors) was characterized by highest 
increases in LSD1, REST, and USP7 expression of all clusters, while cluster 5 (SHH Γ 
tumors) exhibited the opposite pattern, with low expression of these genes (Figure 57). 
Cluster 3 (subset of SHH α tumors) exhibited LSD1 expression comparable to that in 
cluster 2, but more intermediate levels of REST, and USP7 expression remained 
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unchanged from cluster 1. Cluster 4 (SHH-ß tumors) also had high expression of REST 
and LSD1 genes, but not USP7 (Figure 57). Tumors in clusters 5 (SHH Γ tumors) and 6 
(variable sub type distribution) exhibited elevated LSD1 expression, without co-elevation 
of REST or USP7 (Figure 57). These results indicate that co-elevation of REST and LSD1 
transcript or increased stability of REST and LSD1 proteins could occur in subsets of SHH 
tumors. A significant correlation was observed between LSD1 and REST expression as 
well as LSD1 and USP7, (r = 0.40; p<0.0001) and (r = 0.38; p<0.0001) respectively, 
across these 4 clusters (Figure 57).  
Further examination of patient outcomes between clusters 2/3 and 5 revealed a 
higher percentage of patients with metastasis in cluster 2/3 and 4 versus cluster 5 
(Figure 58). Additional studies revealed a significant difference in Mantel-Cox analysis 
of survival curves of clusters 2-4 versus cluster 5 (Figure 58). Together, these results 
suggest that subsets of patients within the SHH α and ß MB type have increased LSD1 
and REST levels or activity and exhibit poor outcomes.   
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Figure 50. LSD1 transcript expression across MB subgroups. Transcript 
expression across subgroups of MB.  
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Figure 51. Survival curves of patients with low, moderate, or high LSD1 transcript 
levels. Overall survival is significant between conditions of low, moderate, and high LSD1 
expression across all of MB patient samples (n=763). Gehan-Breslow-Wilcoxon (GBW) 
examination of early survival revealed a significant difference in early survival between 
low and high LSD1 patients (p<0.05). Mantel-Cox analysis of curves revealed that survival 
curves from moderate LSD1 and low LSD1 patients were significantly different (p < 0.05).  
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Figure 52. Survival curve of Group 3 patients shows significant relationship with 
LSD1 expression. Analysis of survival curves revealed significant differences in early 
and overall survival related to LSD1 transcript expression in Group 3 MB. 
  
121 
 
Figure 53. Survival curve of other MB subgroups. Kaplan-Meier survival curve 
differences between low, moderate, and high levels of LSD1 transcript were insignificant 
in A) WNT, B) Group 4, and C) SHH MB. 
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Figure 54. LSD1 expression in metastatic vs non-metastatic patients. Overall 
expression of LSD1 transcript between patients with and without metastasis A) across all 
MB samples and B) within MB subgroups. T-test analysis of differences in expression 
were insignificant in all cohorts. 
All MB 
WNT SHH 
Group 3 Group 4 
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Figure 55. LSD1 expression in metastatic patients. A) Analysis of patients with 
metastasis revealed that the majority of patients with metastasis had moderate to high 
transcript expression of LSD1. Further, B) LSD1 expression was positively correlated with 
Vimentin and C) negatively correlated with E-cadherin. 
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Figure 56. Clustering of SHH MB patients based on LSD1 target gene expression. 
Clustering of MB patient samples was completed by a lab member, Shinji Maegawa, who 
used 91 genes previously established to be LSD1 target and REST and metastasis 
related genes in the brain. Clusters generated 6 clusters that loosely aligned with 
previously established SHH subtypes.  
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Figure 57. Clusters have distinct patterns of LSD1 and REST expression aligned 
with SHH MB subclassifications. A) Breakdown of SHH MB patient subtypes (alpha, 
beta, delta, gamma) per cluster (cluster 1 n=78; cluster 2 n=34; cluster 3 n=49; cluster 4 
n=26; cluster 5 n=25; cluster 6 n=11). B) Box plots of LSD1 expression. Clusters 2, 3, and 
4 were characterized by high levels of LSD1 and cluster 5 had significantly lower levels 
of LSD1 (*p<0.05; ****p<0.0001). Cluster 1 had significantly lower LSD1 expression than 
cluster 2. C) Box plot of REST expression. Clusters 2, 3, and 4 were characterized by 
high levels of REST and clusters 1 and 5 had significantly lower levels of REST 
(***p<0.001; ****p<0.0001). D) Box plot of USP7 expression. Cluster 2, but not 3 or 4, 
was characterized by high levels of USP7 and cluster 5 had significantly lower levels of 
USP7 (*p<0.05; **p<0.01; ***p<0.001).  E) The expression of REST and LSD1 was 
correlated across 4 clusters (r = 0.40, p<0.0001). F) The expression of LSD1 and USP7 
was correlated across 4 clusters (r = 0.38, p<0.0001). 
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Figure 58. Clusters 2, 3, and 4 have different patient outcomes from cluster 5. A) 
While clusters 2, 3, and 4 are both characterized by high LSD1 and REST, cluster 2 had 
a trend towards the highest amounts of REST and a higher levels or post-transcriptional 
stabilizer USP7. B) Analysis of patient outcomes revealed that patients from cluster 2/3 
and 4 had a 6-fold and 4-fold increased incidence of metastasis. Kaplan-Meier survival 
curves from both Clusters 2, 3, and 4 were significantly lower than that of cluster 5 
(p<0.01). 
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5.2 In vitro experiments 
Genetic ablation of LSD1 expression or activity reduces MB cell viability. 
To examine the requirement of LSD1 for MB cell growth, we used an LSD1-
targeted shRNA in three SHH MB cell lines, UW228, UW426, and Daoy. LSD1 
knockdown significantly reduced cell viability in both cell lines (Figure 59, Figure 60, 
Figure 61). Further, cell growth over time was also blocked by knocked down LSD1. At 
the molecular level, REST elevation increased LSD1 protein levels in both Daoy-REST 
and Uw288-REST cells (Figure 61). These results indicate that both the presence and 
activity of LSD1 is required for MB cell growth and that its repression can block the cell 
growth advantage of REST-expression in MB tumor cells.  
The effect of LSD1 knockdown in the context of REST-overactivation was 
examined, as REST has been shown to protect LSD1 from degradation by maintaining 
the enzyme in complex (87). These results have implications for treating REST-high MB 
cells. Treatment of Daoy-REST cells with LSD1 knockdown also provided significant 
reduction in viability (Figure 61).  
Irreversible inhibition of LSD1 has no effect on cell growth. 
As we were able to demonstrate that both LSD1 function and activity could affect 
cell viability, we next evaluated a panel of irreversible LSD1 inhibitors on cell growth. 
However, within the MTT assay paradigm, we found that none of the irreversible inhibitors 
(tranylcypromine, GSKLSD1, and GSK2789552) had any effect on SHH MB cell lines 
UW228, UW426, and Daoy cells up to a 100 uM dose (Figure 62). Irreversible inhibition 
of LSD1 had no effect on UW228 or Daoy cells with elevated REST expression (Figure 
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63). A full cytotoxicity curve could only be capitulated with a dose range up to 1mM (data 
not shown). 
Irreversible inhibition of LSD1 reduces cell migration. 
Although the effect of the drug had no discernible effect on cell growth in MTT 
assays, previous study had found that LSD1 blockade could reduce the migration of MB 
cells. Using, scratch wound healing assays, we examined the effect of LSD1 inhibition on 
migration in normal and high-REST contexts. Irreversible inhibition reduced migration of 
UW426, UW228, and Daoy cells (Figure 64). While, UW228 cells did not migrate 
significantly in a 24 hour timeframe, UW228 cells with elevated REST expression resulted 
in a two-fold increase in cell migration (Figure 65). A similar two-fold change in migration 
was seen between Daoy and Daoy-REST cells (Figure 66). This migration advantage 
was blocked by LSD1 inhibition in a dose dependent manner using the irreversible 
inhibitor GSKLSD1. Daoy cells migrated more than UW228 cells within a faster time range 
of 18 hours. Further, LSD1 inhibition as low as 5 uM GSKLSD1 significantly reduced cell 
migration of Daoy cells (Figure 66). Daoy-REST cells migrated the most, with a two-fold 
increase compared to their Daoy counterparts (Figure 66). Interestingly, these cells also 
displayed a resistance to LSD1 inhibition at the lower dose, requiring a dose of 75 uM to 
significantly reduce migration.  
We also examined transwell migration of Daoy and Daoy-REST cells to fetal 
bovine serum (FBS). Irreversible LSD1 inhibition at 75 uM was sufficient to significantly 
reduce cell migration over time in both Daoy and Daoy-REST cells (Figure 67). Together 
with the cell viability data, these results suggest that irreversible LSD1 inhibition may have 
a specific functional effect on MB cell migration. 
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Figure 59. LSD1 knockdown or catalytically inactive mutant of LSD1 decreases 
viability of UW228 SHH MB cell line. UW228 cell viability was reduced by genetic 
knockdown and catalytic inactive mutant of LSD1 (n=3; *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001).  
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Figure 60. LSD1 knockdown or catalytically inactive mutant of LSD1 decreases 
viability of UW426 SHH MB cell line. UW426 cell viability was reduced by genetic 
knockdown and catalytic inactive mutant of LSD1 (n=3; *p<0.05).
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Figure 61. LSD1 knockdown or catalytically inactive mutant of LSD1 decreases 
viability of Daoy and Daoy-REST SHH MB cell line. A) Daoy and Daoy-REST cell 
viability was reduced by genetic knockdown and catalytic inactive mutant of LSD1 (n=3; 
p<0.05). B) Protein levels of REST and LSD1 were examined by western blot in isogenic 
cell pairs of UW228 and Daoy.  
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Figure 62. MTT assay with irreversible inhibitors of LSD1 in SHH MB cell lines. MTT 
assay of UW228, UW426, and Daoy cells were completed with three irreversible LSD1 
inhibitors A) Tranylcypromine and Tranylcypromine derivatives: B) GSK2789552 and C) 
GSKLSD-1. Dose-response curves could not be generated in any cell lines or with any of 
the three drugs up to 100 uM dosage.   
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Figure 63. MTT assay with irreversible inhibitors of LSD1 in isogenic REST-
transgene SHH MB cell line pairs. MTT assay of isogenic cell pairs A) Daoy/Daoy-
REST and B) UW288/UW228-REST were completed with three irreversible LSD1 
inhibitors (Tranylcypromine and Tranylcypromine derivatives: GSKLSD1 and 
GSK2879552). Dose-response curves could not be generated in any cell lines or with any 
of the three drugs up to 100 uM dosage.   
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Figure 64. Irreversible LSD1 inhibition reduces wound healing migration in SHH 
MB cell lines. Scratch wound healing assay was performed to examine the effect of 
LSD1 inhibition on migration using UW228, UW426, and Daoy cells. A panel of 
irreversible LSD1 inhibitors were used: A) Tranylcypromine and tranylcypromine 
derivatives: B) GSK2789552 and C) GSKLSD1. A low dose of 5 uM and a higher dose 
of 75 uM were used, neither which had any effect on cell growth in MTT. In most cases, 
a low dose of 5 uM was enough to reduce migration. (n=3; *p<0.05 **p<0.01).  
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Figure 65. GSKLSD1 reduces wound healing migration of UW228 and UW228-
REST cells. Scratch wound healing assay was performed to examine the effect of 
LSD1 inhibition on migration of isogenic cell pair UW228 and UW228-REST. UW228 
cells did not migrate much over a 24 hour period. UW228-REST cells migrated two-fold 
and a dose of 5 uM was sufficient to reduce migration (n=3; *p<0.05 **p<0.01).  
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Figure 66. GSKLSD1 reduces wound healing migration of Daoy and Daoy-REST 
cells. Scratch wound healing assay was performed to examine the effect of LSD1 
inhibition on migration of isogenic cell pair Daoy and Daoy-REST. A dose of 5 uM was 
sufficient to reduce migration in Daoy cells. However, Daoy-REST cells migrated two-fold 
compared to Daoy and required 75 uM to significantly reduce migration (n=3; *p<0.05).  
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Figure 67. Irreversible LSD1 inhibition reduces IncuCyte transwell migration in 
Daoy and Daoy-REST cell lines. Time-coursed transwell migration assay was 
performed to examine the effect of LSD1 inhibition on migration of isogenic cell pair 
Daoy and Daoy-REST using the incucyteZOOM system. Administration of 75 uM of 
GSKLSD1 flattened the slope of cell migration of both Daoy and Daoy-REST cells.  
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5.3 Analysis of RNA-sequencing data to determine targets of REST and 
LSD1 
RNA-sequencing data demonstrates that irreversible inhibition of LSD1 
functionally blocks migration machinery and reduces REST-dependent increase of 
HIF1A.  
In order to obtain a better understanding of the molecular mechanism behind the 
peculiar specificity of LSD1 inhibition on cell migration, we treated Daoy cells with 75 uM 
of GSKLSD1 and performed RNA-sequencing. RNA-sequencing analysis revealed 451 
significantly altered genes with 200 being upregulated and 251 being repressed by LSD1 
inhibition (Figure 68). Functional analysis of these genes revealed several significant and 
relevant functions to cancer. These functions included cancer, cell death, cell adhesion, 
and migration. Further analysis of these cell migration and adhesion function illuminated 
several molecules of interest including previously established LSD1 target bone 
morphogenic protein 2 (BMP2) and HIF1A (Figure 69). However, previous report had 
found that LSD1 knockdown restored BMP2 expression in MB cells. Interestingly, we 
found that while knockdown did indeed increase BMP2 expression, GSKLSD1 inhibition 
of LSD1 had the opposite effect (Figure 70). Although analysis of patient data examining 
BMP2 reinforced previous findings, showing that BMP2 and LSD1 are indeed negatively 
correlated. Although BMP2 was not increased with GSKLSD1 inhibition, REST related 
expression of HIF1A was reduced (Figure 71). HIF1A has been linked to both heightened 
REST and monoamine oxidase (MAO) inhibitors, such as Tranylcypromine (90). While 
these results may suggest that off target effects may be occurring with the use of 
tranylcypromine-derivative, GSKLSD1, they also show a beneficial effect of these 
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inhibitors on migration. Further, GSKLSD1, and other analogs of tranylcypromine, have 
an N-amine substituent increasing its specificity for LSD1. Further previous studies have 
demonstrated a role for LSD1 in regulating HIF1A expression and protein stability. While 
REST normally acts as a repressor at the gene promoter of HIF1A, among other targets, 
the role of cytoplasmic REST and LSD1 in the context of proteosomal stabilization or 
nuclear localization and function of REST has yet to be explored (91, 92). Additionally, 
increased REST expression has been shown to influence REST expression to a more 
cytoplasmic localization that can increase the stability of proteins (93). In line with these 
postulations, HIF1A was positively correlated with LSD1 and REST and patient samples 
(Figure 72). 
However, it is important to note that in these experiments LSD1 inhibition nor 
knockdown in Daoy and Daoy-REST cells resulted in global dimethylation changes at 
H3K4 or H3K9 residues as measured by western blot of histones purified by acid 
extraction (Figure 73). 
REST has been previously linked to HIF1A expression and activity. However, 
these results are the first to show that LSD1 is involved in REST-dependent HIF1A 
expression especially in a positive manner (Figure 71, Figure 72). Further, while 
GSKLSD1 had no effect on BMP2, GSKLSD1 inhibition did reduce HIF1A levels which 
were positively correlated with REST expression in patient samples. These findings 
provide a novel target for REST and LSD1 coactivity as a stabilizer of HIF1A expression. 
Although, off-target effects of GSKLSD-1 cannot be excluded and these effects warrant 
further investigation.  More studies are necessary to examine subgroup-specific changes 
in LSD1 target genes. 
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Figure 68. RNA-sequencing and functional analysis of irreversible LSD1 inhibitor 
treated Daoy cells. Daoy cells were treated with 75 uM of GSKLSD1 and submitted for 
RNA-sequencing. A) Volcano plot shows that a subset of genes were significantly altered 
(red dots; p<0.05). B) IPA analysis of significantly altered functions revealed several 
functions of interest, including cancer (not pictured here), cellular death, and cell 
movement (p<0.01). 
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Figure 69. Heatmap identifies genes involved in cell adhesion and migration 
function altered by irreversible LSD1 inhibition. Genes from cellular adhesion and 
migration revealed HIF1A, but not BMP2, as a target of LSD1 inhibition.  
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Figure 70. BMP2 expression is upregulated by LSD1 knockdown but not 
irreversible inhibition.  A) qPCR of Daoy and Daoy-REST cells treated with shLSD1 or 
GSKLSD1 revealed that BMP2 was differentially regulated (n=3; *p<0.05). B) Analysis of 
patient data revealed that LSD1 and BMP2 were indeed correlated and related to clusters 
2, 3, 4, and 5 in a REST and LSD1 dependent manner (****p<0.0001).
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Figure 71. Irreversible inhibition of LSD1 reduces HIF1A expression in the context 
of endogenous and elevated REST levels. qPCR of isogenic cell pairs of Daoy and 
UW228 cells treated with GSKLSD1 revealed that HIF1A was reduced (n=3; **p<0.01; 
****p<0.0001).   
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Figure 72. HIF1A is correlated with high REST and LSD1 levels in patient samples 
between clusters 2 and 5. A) Analysis of patient data revealed that LSD1 and HIF1A 
were correlated along with REST expression in clusters 2, 3, and 5 (***p<0.001). B) 
Interestingly, cluster 3 trended differently than cluster 2.  
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Figure 73. Histone extraction reveals no change in global dimethylation of H3K4 or 
H3K9 in response to inhibition or knockdown. Global changes were not detectable in 
response to LSD1 targeting in Daoy or Daoy-REST cells.  
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In brief, the combination of these results highlight the potential of targeting LSD1 
function in the context of high REST. LSD1 is elevated in MB samples is related to lower 
survival in patient samples. Further, the coactivity of LSD1 and REST seems to be 
specifically relevant in subsets of patients clustered by LSD1 target genes (clusters 2 and 
3). These clusters mostly aligned with SHH alpha subtypes. When contrasted with 
patients clustered with lowered levels of LSD1 and REST (cluster 5), significant 
differences in overall survival were observed. In in vitro experiments, LSD1 knockdown 
and genetic inactivation reduced SHH MB cell line viability over time. Further, REST 
overexpression in UW228 and Daoy cells (UW228-REST, DAOY-REST) resulted in 
increased LSD1 protein levels and increased cell growth in Daoy-REST cells. These cell 
growth advantages were blocked by LSD1 knockdown. Interestingly, use of irreversible 
inhibitors derived from the MAO inhibitor, Tranylcypromine, had no effect on cell growth 
on SHH MBs with or without high REST expression. However, within the same dose 
range, irreversible LSD1 inhibition reduced cell migration as measured by scratch wound 
healing assay. Transwell migration of isogenic cell pair Daoy and Daoy-REST revealed 
that LSD1 inhibiton significantly reduced migration as well. Daoy cells with endogenous 
levels of REST treated with LSD1 inhibitor were submitted for RNA-sequencing to identify 
expression changes occurring with inhibition. Functional analysis of RNA-sequencing 
data revealed several significantly altered functions including cancer and cellular 
movement. Closer analysis of gene expression changes revealed a previously 
established target, BMP2, with an opposite expression pattern of expression from genetic 
knockdown, that was confirmed with qPCR.  Another LSD1 target, HIF1A, was also a 
candidate from the RNA-sequencing. HIF1A transcript expression was verified to reduce 
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with LSD1 inhibition in the context of both low and high REST. Analysis of the patient data 
revealed a significant positive correlation of REST and HIF1A along with LSD1. These 
preliminary results are the first to suggest that LSD1 may positively regulate HIF1A in the 
context of REST. 
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Chapter 6:  
Discussion and Future Directions 
  
152 
 
The need for targeted therapies in pediatric MB is dire. While subsets of patients 
have good prognosis and an 80% five-year event free survival, other subsets of patients 
experience heightened rates of metastasis and recurrence (2, 6). For these patients, 
standard care does little to ease tumor progression and aggressive treatments can 
severely reduce quality of life without guarantee of efficacy. Even when successful, 
radiation therapy increases the risk of neurocognitive defects when used on younger 
patients. Outside of these options, hospice care is the only remaining comfort that the 
clinic can offer. Personalized medicine will pave the way to target tumor cells without 
affecting normal tissues as much. While radiation and chemotherapy are still our best 
tools for fighting tumor growth, it is the hope of the cancer field that, while we can initially 
work in conjunction with these tools, we can reduce our use of these aggressive and 
nonspecific therapies.   
In order to develop and utilize targeted therapies, we first have to understand the 
underlying biological mechanisms of tumor progression and development. Understanding 
the rational for molecular targeting allows for strategies such as synthetic lethality to be 
successful. Synthetic lethality is a principal discovered in drosophila experiments 
demonstrating that a given organism will die when the expression of two genes is 
simultaneously blocked but that blockade of either gene in isolation has no effect on 
organismal viability (94, 95).  
The principal of synthetic lethality gained traction in the cancer research 
community in the early 21st century. Due to the existence of several redundant cellular 
mechanisms regulating homeostasis, metabolism, and cell cycle progression, there are 
many molecular hurdles that a normal cell must pass to transform into a tumor cell. In 
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fact, for many cells there are several proteins and pathways with redundant functions. 
This acts as a fail-safe that allows cells and tissues to overcome injuries over time. This 
principle is exactly why cancer is largely viewed as a disease of aging. Over time, our 
aging tissues accumulate insults and injuries that contribute to the formation of mutations. 
Genetic predispositions, meaning having inherited mutations in oncogenes or tumor 
suppressors, contribute to the ever-growing checklist of “hits” that your cells can take. In 
the same way, risk factors that directly injure your tissues or increase the generation of 
harmful reactive oxygen species can also increase the likelihood of mutations. When 
these mutations accumulate in such a way that cell growth goes unchecked, cells can 
grow out of control and become tumors. Further, tumorigenic cells are often also 
programmed to evade immune system checks and apoptosis. Because tumor cells are 
hallmarked by genetic instability and loss-of-function mutations in tumor suppressor 
genes, there are many cases where tumors become “addicted” to the expression of 
certain genes that allow them to proliferate even though they are genetically handicapped 
in many ways. This is the primary reason that tumor cells can be prime candidates for 
synthetic lethality. Let’s say that genes A and B are two redundantly-similar genes that 
promote survival, normal cells are able to utilize both gene A and gene B pathways. Due 
to the accumulation of mutations over time, a tumor cell lost gene A and it is now 
dependent on gene B for survival. Now a clinician administers a drug that blocks the 
function of gene B. Normal cells will switch over to gene A to survive while the tumor cell 
will die. This is synthetic lethality. This landmark cancer therapeutic strategy was first put 
to use in breast cancer with mutations in BRCA 1/2 in 2005 (96). BRCA 1/2 are molecules 
important for repairing double-stranded DNA breaks. Loss-of-function mutations in BRCA 
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1/2 predispose individuals to breast cancer. Another molecule involved in repairing single-
standed breaks is PARP1. When tumor cells with BRCA 1/2 mutations are targeted with 
PARP1 inhibitors, they are unable to overcome the load of DNA-damage and perish. This 
principal is now being applied to several different types of cancers, including MB. 
However, a greater understanding of molecular mechanisms of tumorigenesis is required. 
Synthetic lethality is a quintessential example of how heightened mechanistic 
understanding allows for successful targeted therapeutics. The goal of my work has been 
to uncover targetable mechanisms for MB metastasis and progression. 
Our lab and others has demonstrated that REST is a driver of MB progression and 
leptomeningeal dissemination. REST is a canonical regulator of brain development. Its 
expression is downregulated during neuronal lineage specification, which results in de-
repression of expression of its target neuronal differentiation genes (54-57). REST levels 
are elevated in the pediatric brain tumor MB, and are associated with a poor overall and 
event free survival (47).However, the mechanisms of the role of REST in these processes 
were under investigated. While it was demonstrated that REST alone cannot generate 
tumors, we found that REST expression could alter the molecular properties of granule 
neuron progenitors in the cerebellum. Further, these cells with upregulated REST were 
more sensitive to chemokinesis and had issues organizing correctly in the cerebellum. In 
the context of SHH MB, an increase in REST expression in GNPs in the context of 
constitutive activation of SHH signaling drove an aggressive disease course associated 
with increased tumor penetrance, decreased latency, and leptomeningeal dissemination 
of MB cells. Fortunately, these results have also provided mechanistic insights into normal 
postnatal cerebellar development and how it is co-opted during tumorigenesis, which is 
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consistent with the notion that MB is a disease of normal development gone awry (21, 24, 
31,32). 
The cerebellum is the most frequent site of MB growth and is unique for many 
reasons. Its complex perinatal development, which can last up to two years after birth, 
makes it vulnerable to insult and malformation (21-23). Successful cerebellar 
development requires a multitude of coordinated cellular and molecular processes, the 
study of which has been pivotal to understanding MB genesis. An aspect that is of 
particular relevance to this study involves the developmentally regulated expansion, 
migration, and differentiation of GNPs. Our work described here is the first to demonstrate 
that deregulated expression of REST perturbs the directed migration of GNPs from the 
EGL to the IGL during normal postnatal cerebellar development. Probing the RNA-
sequencing data with the observation that many of the migration defects take place in the 
progenitor-populated EGL and at the meningeal barrier led us to more carefully 
investigate a hypothetical connection between REST elevation and changes in CXCR4 
signaling. The CXCR4 pathway is vital to proper guidance of GNPs in the EGL before 
they commit to radial migration to their final destination in the IGL (39). Genetic loss of 
CXCR4 or SDF1 causes premature GNP migration and foliation defects (96, 97). The 
meningeal epithelium is known to secrete SDF1, which is a ligand for the chemokine 
receptor CXCR4 present on GNPs. This interaction may spatially constrain GNPs within 
the outer EGL, where they undergo a rapid proliferative phase and expansion coincident 
with tangential migration (39, 98, 99). While the effects of CXCR4 and SDF1 knockdowns 
on cerebellar development have been extensively studied, the consequences of CXCR4 
elevation is still unknown. In our mouse model, REST represses BDNF expression, which 
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has been demonstrated to negatively regulate CXCR4 activity. These molecular events 
may favor a state in which cells are restrained within the EGL space, and possibly even 
facilitate tangential migration.  
REST elevation also upregulates ERK levels at the protein level, suggesting 
affected downstream signaling. While it is unlikely that REST regulates ERK at the 
transcriptional level, REST has been demonstrated to be capable of inhibiting 
ubiquitinases which may be a means of protein stabilization (46). This idea may be 
strengthened by our observation that while SDF1 transcript was down in our RNA-
sequencing data, the protein levels were increased. This is an observation that we see 
often in our REST-expressing cells, somewhat surprisingly as REST is a canonical 
repressor. However, repression of players in protein degradation pathways or differential 
functions of REST in the nuclear/cytoplasmic compartments could be an interesting 
explanation for this phenomena. In line with this, previous preliminary work has 
demonstrated that high levels of REST result in increased cytoplasmic expression that is 
capable of stabilizing luciferase-tagged proteins in vitro (100). Further studies are needed 
to eludicate the role of REST in the protein degradation pathway.  
An ongoing study under review has shown that REST also regulates proliferation 
of SHH MBs, a subgroup of which arise from GNPs. The proliferative phase undergone 
by GNPs in the EGL is followed by the onset of neurogenesis, marked by a decline in 
REST levels, derepression of REST target neuronal differentiation genes, and is 
accompanied by radial migration across the molecular layer to its final destination in the 
IGL. Radial migration of differentiating neurons requires radial glial processes as a 
scaffold (98). The number and organization of these cells seem to be abnormal in the 
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cerebellum of RESTTG mice. The molecular reasons underlying this phenomenon is not 
clear, but it would be reasonable to speculate that cell-cell communication and 
dependency may be bi-directional between neurons and radial glia (10, 13, 22, 101, 102). 
Although, the scope of this work does not include neuron-glia interactions, the importance 
of these interactions is an apparent future direction of this work. Further, other work on 
our lab has focused on understanding how REST and SHH signaling cooperate to 
promote tumorigenesis. As REST is being expressed in the same GNPs that are 
responding the SHH secreted by the purkinje cells, the opportunity for cooperativity 
between the two pathways is present. In the scope of mechanisms of SHH signaling 
regulation, so much is still unknown about interactions after Smo activation that stabilize 
Gli and allow nuclear translocation. Current postulations include differential 
phosphorylation of Gli into active 1 and 2 states that translocate. Nothing is known about 
what happens to phosphorylation regulators that direct Gli for ubiquitnation and NH2 
terminal truncation into Gli 3. A paper currently being published in our lab speculates on 
the role of REST in Gli stabilization and transcription along with a role for REST in 
transcriptional repression of the PTCH1 receptor. 
CXCR4/SDF1 engagement can result in activation of a number of downstream 
signaling cascades, including ERK, AKT, and calcium signaling (39, 42). REST and 
CXCR4 seem to be expressed in MB in a cooperative manner and while we saw a 
decrease in REST-dependent migration, the effect of CXCR4 antagonism by AMD3100 
was modest. This may be due to additional mechanisms of increased migration by the 
tumor. Additionally, the patient data we analyzed suggests a strong dependence of these 
effects on SHH signaling and imply a subtype-specific effect. The cooperativity of REST 
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and CXCR4 seem to peak in SHH-beta and SHH-delta subgroups. Further studies 
determining the subgroup of commercially available cell lines, like UW228 and Daoy, may 
allow more precise experiments on these molecular interactions. Our results described 
here along with previous studies in other labs highlight the importance of understanding 
how molecular signaling in different subgroups contribute to individual differences in 
tumor genesis and progression (7, 8, 103,104).  
The work of chapters 3 and 4 of this dissertation is the first to link REST to the 
regulation of GNP migration and to the regulation of CXCR4/SDF1 signaling, providing 
the groundwork to explore the potential of targeted therapeutic options for a subset of 
SHH patients experiencing tumor dissemination with increased REST expression. We 
also examined the expression levels of known REST target brain-derived neurotrophic 
factor (BDNF) in the tumor environment as BDNF has the potential to inhibit CXCR4 
activity. We demonstrate that REST elevation can reduce BDNF and increase CXCR4 
and SDF1 expression, molecules with established roles in both normal cerebellar 
development and in MB. These studies opens the door to exploring CXCR4 blockade as 
a therapeutic option for a subset of patients. Our findings not only provide an additional 
facet to REST’s contribution to SHH-specific MB development, but also highlight the 
potential of disrupting the highly regulated normal postnatal cerebellar development in 
tumorigenesis. 
Other studies have shown that increased signaling through AKT, outside of 
CXCR4 activation, can also influence migration (105-108). It may be necessary to use 
combination therapy to target multiple pathways including CXCR4 and AKT in order to 
completely block migration. Altogether, REST is an attractive molecular target for 
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pediatric brain cancers including MB. Recently, labs are making more selective inhibitors 
for REST complex activity for use in these contexts (74). Outside of these intriguing small 
molecule inhibitors, other drugs are already on the market for REST complex partners 
with epigenetic activity. Some that our lab have worked with include REST-coREST 
partners LSD1, a lysine-specific demethylase which has been implicated in MB cell 
growth and the methyltransferase G9a, which has been demonstrated to play a role in 
the cell growth and proliferation of MB human cell lines (46, 73, 74, 78, 79).  
The work completed with the aim of targeting LSD1 in the context of REST has 
demonstrated some interesting results. The work completed has demonstrated that LSD1 
is necessary for cell growth of SHH MB, both in the context of high and low REST. 
However, low-potency irreversible inhibition of LSD1 reduces cell migration of SHH MB 
in a REST-dependent manner. This inhibition is paired with reduced HIF1A expression. 
Interesting results from this aim raises questions about specific functions of LSD1 and 
also highlighted the importance of specific targeting strategies against LSD1. The fact 
that genetic knockdown of LSD1 resulted in a different expression pattern than 
irreversible inhibition warrants further investigation into the mechanism of action of 
different classes of inhibitors. Some clinical observations have stated that inhibitors only 
partially targeting enzyme activity can not only have off-target effects but can sometime 
result in unintended compensatory activity. 
Along these lines, a new class of inhibitors against LSD1 is being explored. With 
a different mechanism of action, these new inhibitors are considered to be reversible 
inhibitors. Tranylcypromine, GSK2789552, GSKLSD1 all irreversible, tranylcypromine 
derivatives that act on FAD enzyme activity to inhibit oxidative process necessary for 
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demethylation (109). Amine-containing N-substituents added introduced to 
tranylcypromine moiety increased inhibitory activity and lent the drugs with more 
specificity to LSD1. New reversible inhibitors of LSD1 have been developed by Salarius 
pharmaceuticals and include SP2509 and SP2557. SP2577 is a derivative of SP2509, a 
reversible LSD1 inhibitor that acts by preventing LSD1 binding to cofactors like coREST 
(110). Sp2577 is the more potent that commercially available inhibitors and its mode of 
action is different than the three used previously. Although the irreversible, 
tranylcypromine-derived drugs were stouted to be LSD1 specific due to not having an 
effect on cell growth of over 100 other cell lines (111), other reaction phenotypes outside 
of cell growth were still seen by treatment in studies done by our lab and others. Further, 
preliminary results have shown that genetic knockdown, inactivity, and indeed use of the 
reversible inhibitor sp2577 proved to inhibit SHH MB cell growth and viability (data not 
shown).  
Another point of interest is that REST and CXCR4 cooperativity appears to occur 
most relevantly in SHH ß subgroup of MB. On the other hand, LSD1 activity appears to 
be the most relevant in the SHH α subgroup. While SHH ß subgroup has the highest 
amount of metastasis, the age range of patients is on the lower end with most patients 
being 0-3 years of age. The SHH α patients on the other hand are still pediatric but take 
place in older children. These patients have the second highest incidence of metastasis. 
As SHH ß patients still have developing cerebella (with postnatal cerebellar lamination 
continuing until the age of 2 years), it is encouraging that our results suggest that yet 
another developmental pathway (CXCR4) cooperates with REST in a manner that 
promotes tumorigenesis and dissemination. In the older pediatric patients of the SHH α 
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subgroup, we see a different mechanism independent of this developmental CXCR4 
signaling. Instead these patients seem to be more sensitive to the increased levels of 
epigenetic histone modifier, LSD1. That REST cooperates with different pathways 
depending on the availability of these programs suggests that elevated REST could be 
coordinating with several programs to drive MB tumorigenesis and dissemination.  
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